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Abstract
The family of insulin- like growth factor 2 mRNA binding proteins (IMPs) contains three
members: IMP1, p62/IMP2 and IMP3. All these proteins are oncofetal proteins, expressed
during embryogenesis and lost in most tissues in adults. However, p62/IMP2 were found
overexpressed in various cancers but its function in carcinogenesis remains to be investigated.
Our previous studies found that p62/IMP2 was not only overexpressed in hepatocellular
carcinoma (HCC) tissues, but also overexpressed in HCC cell lines. To explore the biological
roles of p62/IMP2 in HCC progression, p62/IMP2 was knockout in two p62/IMP2 positive HCC
cell lines (SNU449, HepG2). Due to the low expression level of p62/IMP2 in SNU449, we
overexpressed p62/IMP2 in this cell line. The results from both of wound healing assay and
transwell migration assay indicated that overexpressed p62/IMP2 in both cell lines could
promote the cell migration significantly (p<0.05).

On the contrary, the lack of p62/IMP2

expression can reduce the cell migration ability (p<0.05).

After analyzing the HCC expression

data from Gene Expression Omnibus (GEO), the high and low p62/IMP2 expression groups were
set up based on the median expression of p62/IMP2 from GSE 14520. CTNNB1 was selected in
differential gene expression analysis with a cancer-metastasis related gene profile.
Subsequently, western blotting analysis was performed to explore the effect of overexpressed
p62/IMP2 on Wnt/β-catenin pathway-related proteins, and we found that overexpressed
p62/IMP2 can significantly enhance the expression of Wnt and β-catenin, whereas inhibiting the
vi

expression of Gsk3b and E-cadherin. A Wnt/β-catenin signaling pathway inhibitor XAV939 was
used for confirming the results. Nevertheless, although β-catenin expression dramatically
reduced in p62/IMP2 knockdown SNU449 cells, their colony formation ability was still
enhanced by activating Wnt5-induced non-canonical Wnt signaling. In addition, we validated
our results at the phosphorylation level by using Wnt pathway phosphoproteome chips. In
summary, our data showed that overexpressed p62/IMP2 can enhance the migration ability of
HCC cells via activating Wnt/β-catenin.
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Chapter 1 Background and significance
1.1 Hepatocellular Carcinoma
1.1.1 Epidemiology and etiology
Liver cancer is one of the most frequently occurring malignant tumors in the world, which
has a high mortality rate. Liver cancer can be divided into two major categories: primary liver
cancer and secondary liver cancer. The cancer which originates and grows in the liver cells is
called primary liver cancer. The liver metastasis transferred from cancer originated in other
organs of the body is called secondary liver cancer. [1].

Primary liver cancer is the sixth most common cancer (about 850,000 new cases each year)
and is the second leading cause of cancer-related deaths (about 800,000 annually) in the world
[2,5]. Hepatocellular carcinoma (HCC) is one of the most common primary liver cancers, which
accounts for about 90%. In the United States, there were estimated 40,710 new cases of primary
liver cancer, of which HCC accounts for three quarters of all cases [3]. The ratio of men to
women for HCC in global distribution is 2.4, and the most common age when HCC is diagnosed
is usually between 30 and 50 years [4]. HCC occurs mainly in developing countries, including
China, Mongolia, Southeast Asia, and sub-Saharan West Africa and Eastern Africa. With
exception of Japan, Italy and France, the incidence of HCC in developed countries is low [2,5].
However, it is worth noting that from 1980 to the present, the incidence of liver cancer has
increased by 43% in the United States and has increased at a rate of 4% per year [6].
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Adapted from Laursen, L. A preventable cancer. Nature 516, S2–S3 (2014), Nature Publishing
Group

Figure 1. The global burden of HCC

HCC occurs predominantly in patients with liver cirrhosis [7], so risk factors often include
factors that may contribute to chronic liver disease that leads to cirrhosis. The known risk factors
include hepatitis B [8] or hepatitis C infection [9], alcohol abuse [10], aflatoxin [11], iron
overload (hemochromatosis) [12], nonalcoholic steatohepatitis [13] and type 2 diabetes [14]. The
risk factors for HCC are also different in different regions. China is a high-risk country for HCC,
and chronic hepatitis B infection is found in 90% of cases [5,8]. However, in Japan, chronic
hepatitis C is associated with 90% of cases of HCC. At the same time, another important factor
leading to HCC in these areas is aflatoxin, which is widely found in East Asia and Southeast
2

Asia [11]. In Europe and the United States, hepatitis C and alcohol abuse are the most important
factors leading to HCC [9].

The etiology of HCC has not yet been fully elucidated.

Many studies indicated that HCC

is caused by the accumulation of genomic mutations. In one HCC nodule, the coding region
within the genome was accumulated with an average of 40 functional somatic mutations [15, 16].
This can lead to the activation of several cancer-related pathways in HCC. First, the
WNT-β-catenin pathway is frequently activated in patients with liver cancer [17, 18], triggering
a more aggressive HCC phenotype [104]. The mutations in its associated gene, such as CTNNB1,
Axin1, APC, and ZNRF, are also frequently observed in patients with HCC [15]. Second, RB1,
CDKN2A, and other tumor suppressor genes are frequently founded mutated in HCC.
Inactivation of p53 and alternations in cell cycle also occur frequently in HCC [15, 19]. The third,
RAS-RAF-MAPK and PI3K-AKT-mTOR pathways are also frequently activated in HCC [15].
Studies have shown that they are associated with FGF3, FGF4 and FGF19 amplification, and the
inactivation of TSC1, TSC2, PTEN, RPS6K3, RSK2. In addition, mutations are also closely
related to telomerase overexpression. Two mutations, located at the nucleotide positions 124 and
146 upstream of the ATG, suggest that they can generate new transcription factor binding sites
and regulate Telomere reverse transcriptase mRNA expression. In 60% of HCC cases, the TERT
promoter contains mutations, whereas telomerase is overexpressed in 90% of HCC cases [20].
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1.1.2 Staging, Diagnosis and Treatment
The traditional methods for diagnosing HCC include imaging examination and blood tests.
The majority of patients with HCC develop from chronic liver disease and cirrhosis, so related
high-risk groups are recommended to use ultrasound for screening. In addition, CT scans and
MRI can be used to diagnosis HCC [21,22]. The Liver Imaging Reporting and Data System
(LI-RADS) is applicable to HCC for high risk groups. LI-RADS can be used regardless of the
presence of nodules in previous ultrasound or other imaging check. If the mass has been treated,
it should be classified as LR-treated. Benign and high-possibility benign lesions were classified
as LR-1 and LR-2, respectively. If the lesion appears to be a malignant tumor such as
cholangiocarcinoma, it should be classified as LR-M (possibly malignant tumor but not
specifically HCC). In this case, biopsy is required for confirmed diagnosis. If there is a clear vein
thrombus, regardless of whether the primary tumor can be observed, it should be classified as
LR-5V. This can be diagnosed as a malignant lesion. Although intravascular tumor emboli are
most common in HCC, intrahepatic cholangiocarcinoma may also be accompanied by atumor
emboli. Based on specific criteria, lesions can also be classified as LR-3, LR-4, LR-5 [23].

Blood tests are also an essential procedure for the early diagnosis of HCC. At present,
alpha-fetoprotein (AFP) is the most widely used serological marker in the diagnosis of HCC, but
its specificity is not very high [24]. Therefore, AFP is not an optional biomarker for screening
HCC. In recent years, research on autoantibodies to tumor-associated antigens (TAAs) is
becoming a challenging area in the early diagnosis of HCC. As early as the 1960s, Robert W.
4

Baldwin showed that the human immune system can produce autoantibodies in the early stage of
cancer development. A widely accepted viewpoint in cancer research field is that mutations,
ectopic or recombination can occur early in the development and progression of tumor cells.
During tumorigenesis and progression, specific protein products which were excreted by tumor
cells, or released, shed by necrosis of cells are recognized by the immune system to produce
antibodies against the antigen, which is called tumor-associated autoantibodies [25-27].

Many

new TAAs, such as CAPERα/HCC1.4 [28], p62/IMP2 [29] and CIP2A/p90 [30], have been
discovered with certain clinical values in the early diagnosis of HCC.

Unlike the TNM staging system, which is used for most tumors, the Barcelona Clinic Liver
Cancer (BCLC) staging system is used for HCC [31]. The introduction of this system will help
assess the patient's condition, provide accurate treatment options and predict patient outcomes.
The clinical staging system for BCLC liver cancer was proposed by Llovet in 1999 and later
revised by the American Association for the Study of Liver Diseases （AASLD) in 2005 [24].
Table 1 shows the BCLC staging and the corresponding treatment plan.

Table 1. BCLC staging and preferred treatment plan
Stage

Disease condition description

Stage 0 (very early stage)

The patient is in good Surgery
condition and has a single
Ablation for patients who are
tumor with a diameter of less
not suitable for surgery [32]
than 2 cm. His liver function
is well maintained.
5

Preferred treatment plan

Stage A (early stage)

The patient is in good health, Liver transplantation/surgery
with a single to three tumor
Ablation for patients who are
nodules less than 3 cm in
not suitable for surgery [32]
diameter, with good liver
function maintenance

Stage B (intermediate stage)

Cannot
be
surgically Transcatheter
removed, the patient has chemoembolization
multiple
nodular [33]
asymptomatic tumors, no
invasive growth, and good
physical condition

Stage C (advanced stage)

Cannot
be
surgically Sorafenib [34]
removed,
patients
have
cancer-related
symptoms
affecting
physical
state,
symptomatic tumors, portal
vein
invasion,
and
extrahepatic spread (lymph
node metastases)

Stage D (end-stage)

Cannot
be
surgically Palliative care [32]
removed,
patients
have
extensive metastases, and
their physical condition is
very poor

arterial
(TACE)

Just a few years ago, sorafenib was the only drug that proved effective for advanced HCC
treatment [34]. In recent years, with the in-depth study of the tumor microenvironment,
researchers have discovered that the accumulation of a large number of gene mutations leads to
the production of multiple antigens in occurrence and development of HCC, which can be
recognized and specifically killed by the immune system [35]. At the same time, HCC cells can
evolve, thereby to evade the body's immune surveillance through a variety of mechanisms.
6

Studies have confirmed that persistent viral infections and tumor neoantigen stimulation result in
the formation of immunosuppressive states in the liver and promote development of HCC [36].
Cell populations with immunosuppressive functions such as regulatory T cells (Treg) and
myeloid-derived suppressor cells (MDSC) are significantly up-regulated. In addition, the
continuous exposure of antigens causes the tumor-specific lymphocyte surface to over-express
inhibition signaling molecules, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4),
programmed cell death 1 (PD-1), lymphocyte activation gene-3 (LAG-3), consequently leaving
T cells in a state of disability [37, 38]. Therefore, against the mechanism of immunosuppression
in HCC, reverse the disability state of T cells and exert their anti-tumor effect is an important
direction of HCC immunotherapy.

PD-1/PD-L1

PD-1 is a member of the CD28 superfamily that binds to ligands PD-L1 or PD-L2 and
transmits a co-suppressor signal to T cell receptors [39]. It is mainly expressed on the surface of
activated T cells and can also be expressed on B cells, Treg cells, NK cells and MDSC. Its
ligands PD-L1 and PD-L2 are mainly expressed in macrophages, monocytes and other
inflammatory cells [40].

Activation of T cells requires two signals, the first signal from the specific binding of TCR
and antigen, and the second signal from the activation of accessory molecules such as
CD80/CD28 [41]. When PD-1 on the surface of T cells binds to ligand, cytoplasmic tyrosine in
7

immuno-receptor tyrosine switch motifs (ITSM) domain of PD-1will be phosphorylated. Then it
can recruit SH2 domain-containing protein-tyrosine phosphatase-2 (SHP-2) to dephosphorylate
ZAP-70 and PI3K in the downstream of TCR and CD28, blocking the activation of T cells [42].

PD-1 can be expressed under the action of inflammatory mediators such as IFN-y. IFN-y can
induce interferon regulatory factor 9 (IRF-9) binding to PD-1 gene promoter, leading T cells to
transcribe PD-1. At the same time, IFN-γ stimulation also up-regulates PD-L1 expression on the
cell surface. In the tumor microenvironment, T cells activate and expand into effector T cells by
recognizing tumor antigens, specifically killing tumor cells, and secreting a large number of
inflammatory factors such as IFN-y. Prolonged antigen stimulation causes activated T cells to
overexpress PD-1, leading T cell incapacitation [43]. Most tumor cells escape the attack of
immune cells in this way [44]. Therefore, the use of blockers to block the interaction between
PD-1 and PD-L1 can restore T cell activity and kill tumor cells.

CTLA-4

CTLA-4 is a protein receptor also known as CD152. CTLA-4 functioning as an immune
checkpoint participate in the inhibitory pathways in the immune system, which play an important
role in self-tolerance. CTLA-4 is produced by Tregs, sharing the same ligands with CD28. In the
process of activating immune cells, antigen-presenting cells (APC) present antigens to T cells
and combine with TCRs to generate a first signal for T cell activation, which also need CD28
bind with CD80/CD86 to generate a second signal. Tregs bind to CD80/CD86 molecules on the
8

T cell surface through CTLA-4, thereby inhibiting the function of effector T cells [45].
CD80/CD86 also expresses on the surface of APC. Regulatory T cells induce APC through
binding of CTLA-4 and CD80/CD86 thereby producing IDO, which also can inhibit the function
of activated T cells and induces T cell apoptosis [46].
1.1.5 The metastasis and Epithelial-mesenchymal transition in HCC
As much as 90 percent of cancer related deaths can be attributed to metastasis rather than
primary tumors [47], and HCC is no exception. According to the BCLC staging system, the
patients with early HCC have a good prognosis, 30%-40% of patients can be cured, and the
overall survival (OS) is more than 60 months. However, the prognosis of advanced stage patients
with portal vein invasion and extrahepatic metastases is poor, whose OS is only 11 months [31].
Despite the remarkable advances in the research, drug development and clinical treatment plan of
HCC in recent years, majority of advanced metastatic HCC patients are still facing desperate
facts that we do not have an effective curable treatment method, but only limitedly extend their
lives.
Epithelial-mesenchymal transition (EMT) refers to a process in which epithelial cells are
transformed into a biological process with a mesenchymal phenotype by a de-differentiation
procedure [48]. EMT plays an important role in the development of many tissues and organs in
embryos [49]. In recent years, many studies have shown that EMT is closely related to fibrosis
and cancer metastasis. Its main characteristics include the reduced expression of cell adhesion
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molecules (such as E-cadherin), up-regulated expression of markers of mesenchymal cells (such
as Vimentin, N-cadherin) and cytoskeletal transformation [50]. Through EMT, epithelial cells
lose their cell polarity and epithelial phenotypes such as their attachment ability to the basement
membrane, and therefore can acquire high interstitial phenotypes such as high migration and
invasion, anti-apoptosis, and ability to degrade extracellular matrix. EMT is an important
biological process for the ability of epithelial cell-derived malignant tumor cells to gain
migration and invasion [48].
EMT is common in HCC patients. As the most important molecular marker of EMT,
E-cadherin is down-regulated in 69% of HCC specimens and is associated with intrahepatic
metastasis and invasion [51]. In patients with metastases, E-cadherin expression was
significantly lower than the patients without metastasis.
The emergence of EMT requires a series of complex signaling pathway cooperation which
are orchestrated by many activated EMT-inducing transcription factors (EMT-TFs). The most
important EMT-TFs include the SNAI family (Snail and Slug), the Twist family (Twist 1, Twist 2,
E12 and E47, and the ZEB family (ZEB 1 and ZEB 2) [52]. All these EMT-TFs can repress the
transcription of E-cadherin by similar mechanisms: to bind with E-boxes which present in the
E-cadherin promoter. In HCC patients, Snail and Twist overexpression are associated with larger
tumor volume, increased relapse rate, shorter overall survival. In vitro experiments have
demonstrated that overexpression of Snail or Twist promotes tumor cell invasion and increases
10

the mesenchymal phenotype of cells [53]. Overexpression of Snail and Twist in Huh7 cells
inhibits E-cadherin expression and induces EMT phenotypic transformation [53]. Besides
increasing cell invasiveness, EMT also protects HCC cells from extracellular signal-induced
apoptosis. For example, EMT can activate epidermal growth factor receptor (EGFR) pathway
and help HCC cells escape apoptosis induced by transforming growth factor-β1 (TGF-β1) [54].
Numerous signaling pathways have been shown to be involved in EMT, including the
TGF-beta signaling pathway, the Wnt signaling pathway, and the Notch signaling pathway. The
TGF-β signaling pathway is a key regulator of EMT and a major inducing factor that plays a
crucial role in development, wound healing, fibrosis and tumors [55]. This pathway is initiated
by a complex of TGF-β family members with cell surface receptors, which are tetramers
composed of two type I and two type II transmembrane protein kinase receptors. This binding
first phosphorylates the TβRII receptor and subsequently activates the TβRI receptor. The
activated TβRI receptor then recruits and phosphorylates the Smad2 and Smad3 proteins in the
cell. The phosphorylated Smad2 and Smad3 can form a trimeric complex with Smad4. As the
Smad trimeric complex are translocated into nucleus, a series of its target gene will be regulated
by other transcription factors. Smad signaling has been found to regulate EMT transcription
factors including Snail1/Snail2 [56], ZEB1/ZEB2 [57], and the expression of Twist [58]. In
addition to the classical Smad signal, TGF-β can also induce EMT through other non-Smad
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signaling pathways, including Rho-like GTPase [59], PI3K/Akt/Mtor 60], extracellular
signal-regulated kinase (ERK) [61], p38 [62], and JNK [63].

Wnt signaling pathway has been extensively studied in tumor progression in past two
decades. So far, 19 different Wnt ligands and 11 transmembrane Frizzled receptors (FZD) have
been found in humans. The binding of extracellular secreted Wnt ligands to FZD and
low-density lipoprotein receptor related protein, (LRP) 5/6L can initiate canonical Wnt signaling
pathway (Wnt/β-catenin signaling pathway) and non-canonical signaling pathway (PKC and
JNK signaling pathway) [64].
Without Wnt signaling cascade activated, β-catenin is rarely existed in cytoplasm. There is a
destruction complex consisting of APC, Axin, GSK3, CK1α and PP2A responsible for the
removal of free cytoplasmic β-catenin [65]. However, while Wnt bind with Fz and LPR5/6, the
function of degradation of β-catenin by destruction complex will be prevented. The activation of
Wnt signaling could trigger the translocation of axin and bind with the cytoplasmic tail of LPR6
which result in the destruction complex loses the ability to bind with β-catenin. In the other way,
activated Wnt-Fz-LPR5/6 complex can cooperate transduce the signaling to cytoplasm, leading
the inhibition of GSK3β [66]. The consequences of Wnt signaling pathway activation allow
β-catenin accumulating in cytoplasm, and finally translocate into nucleus [67].
Once Wnt pathway activated, β-catenin could bind with lymphoid enhancing factor/T-cell
factor, LEF/TCF complex, forming β-catenin/LEF/TCF complex in nucleus. Following, the
12

transcriptional coactivators and histone modifiers, such as Brg1, CBP, Bcl9 and Pygopus will be
recruited by the β-catenin/TCF complex and drive the Wnt target genes expression [68]. As a
result, the transcription of cell cycle related gene such as cyclin D1 and c-myc will be activated,
enhancing the proliferation ability of cells. In addition, a study has found that β-catenin/LEF-1
complex can down-regulate the expression of E-cadherin. Another research demonstrated that
this pathway also plays an important role in EMT induced by hypoxia-inducible factor-1α
(HIF-1α) [69].
Notch signaling pathway plays a crucial role in many physiological and pathological
processes. So far, there are 4 Notch receptors (Notch 1-4) and 5 Notch ligands (Delta-like1,3,4
and Jagged1, 2) were found. Notch ligands and receptors are transmembrane proteins [70].

1.2 Insulin like growth factor 2 mRNA binding protein family
1.2.1 Nomenclature
Due to the family members are identified and assigned different functions in different
biological systems, the nomenclature of the IMPs family in the earlier literature was confusing.
In the past decade, many synonyms have been used in the literature, including IMP, CRD-BP,
VICKZ, ZBP, Vg1RBP/Vera, or KOC [71]. The research scientists in this field finally
discovered that all these proteins belonged to the same RNA-binding proteins (RBPs) family,
which was so-called insulin-like growth factor 2 mRNA binding proteins (IMPs). Many

studies

have demonstrated that IMPs could regulate diverse aspects of cell function during development
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and cancerIn mammals, three IMP paralogs (IMP1-3), also known as insulin-like growth factor 2
(IGF2) mRNA binding proteins 1, 2 and 3 (IGF2BP1-3) have been identified so far. Some
studies also showed that IMPs can regulate the translation of IGF2 mRNA through a
high-affinity binding site [72].

1.2.2 Structure of IMPs
IMPs are highly conserved, and they share a similar structure. The molecular weights of
human IMP1, 2 and 3 family members are 63, 66 and 64 kDa, respectively. The identity of the
overall amino acid sequences approximately is 60-80%. IMP1 and IMP3 are more closely related
members in this family, with 73% amino acid sequence identity [71]. The genes for encoding
IMP1 and IMP3 contain 15 exons, and the gene for encoding p62/IMP2 protein contains 16
exons [73].

All three members have 6 characteristic RNA binding modules, including two N-terminal
RNA recognition motifs (RRMs) and four heteronuclear ribonucleoproteins (hnRNP)
K-homology (KH) domains in their C-terminal regions (Fig.2). All members of the IMP family,
regardless of the organism they express, show a high affinity for binding RNA. The association
with DNA was only reported once for the p62/IMP2 homolog protein Vg1RBP/Vera in Xenopus
[74]. Due to the lack of highly resolution structural information of the IMPs and their complexes
with the target RNA, the current analysis of each domain is based on inferences from
biochemical experiments and structural data from RRM and KH domains in other RNA binding
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proteins. In vitro studies show that KH domains are mainly responsible for RNA binding [75],
while the RRM domain is responsible for protein-protein interactions, protein dimerization, and
stabilization of IMPs-RNA complexes [76]. However, the KH domains could only recognize
short stretch RNAs with weak binding affinities so that a single domain may not be enough to
regulate the translation of target mRNAs. Research indicates that human IGF2BP1 KH domains
3 and 4 form an anti-parallel pseudo-dimer conformation, in which KH3 and KH4 recognize
their targets through sequence-specific interactions, each in contact with the targeted RNA. Two
low-affinity interactions can allow KH3 and KH4 to bind to highly specific RNAs and force their
associated transcripts to adopt a specific conformation [77]. It is worth noting that IMP-RNA
complexes have a long in vitro half-life, suggesting that IMPs play an important role in the
formation and maintenance of stable protein-RNA complexes.
1.2.3 Expression of IMPs
In mice, the expression characteristics of the IMP family are biphasic. IMPs were first
peaked in oocytes and zygotes, and they have another expression peak in embryos from day 10.5
to day 12.5 [72], then they are continuously reduced till birth. In the second trimester, IMPs
could be found in most tissues of embryos. They are expressed most in neurons and epithelial
cells, and they also could be detected in the brain, nasal cavity, zygomatic arch, intestine, tail,
vertebrae, and skin [78, 79].
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After E12.5, the expression of IMPs is differentiated. In E17.5, p62/IMP2 can still be
observed in the brain, nasal cavity, lung, liver, intestine and kidney. IMP3 almost disappeared at
this time; between E12.5 and E16.5, IMP1 expression was only expressed in stem cells with
poorly differentiated levels in the dorsolateral telencephalon (DMT) [80]. IMP1 and p62/IMP2
remained at low levels of expression in some organs until birth, whereas IMP3 was almost
undetectable. Taking into account of the striking different expression in fetal and adult stages,
IMPs are considered to be oncofetal proteins.
1.2.4 Physiological functions
Studies have shown that IMPs play an important role in embryonic development. Members
of the IMP family plays an important role in mRNA processing steps, including localization,
stability, translation, and possible nuclear export [71, 72]. IMP1 deficiency cause defects in the
development of the intestine in newborn mice, and their size are 40% smaller than normal
controls [79]. Also, p62/IMP2 deficiency severely affects the development of neural stem cells in
mice [81]. IMPs do not express or express less in adulthood, but they are found overexpressed in
many types of cancer.

Although this family of proteins was named as IGF2 mRNA binding proteins, IMPs have a
wide range of binding targets. IMP1 was initially described to be involved in the stabilization of
c-myc mRNA [82]. IGF2BP2 and IGF2 mRNA both have 3'-UTR and 5'-UTR binding sites,
which can upregulate its expression and organize its presentation. p62/IMP2 can also organize
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the degradation of c-myc mRNA through a similar mechanism to increase c-myc expression [83].
A comprehensive study showed that 3% of the HEK293 cell transcriptome will be expressed in
IMP1 mRNP particles, which implies the number of IMP1 targets may be over 1000 [84]. IMP1
can allow β-actin mRNA to be localized to the leading edge of fibroblasts, thereby increasing the
migration ability of cancer cells [85,86]. In addition, the IMP1 gene is amplified in breast cancer
and studies have shown that this is associated with the loss of the estrogen receptor [87]. Let-7 is
a family of highly conserved miRNAs with a total of 13 members which promote differentiation
and inhibit tumor growth. IMPs can protect target genes of let-7, such as LIN28A, LIN28B, and
HMGA2 from let-7-dependent silencing, thereby preventing the breakdown of these proteins and
thus enhancing the invasiveness of tumors [88-90]. The role of IMP3 in cancer has also been
extensively studied. It also influences cancer progression by modulating the stabilization and
translation of cytoplasmic fate of mRNAs. IMP3 has been found to have many target genes, such
as CD44 [91], H19 [92], HMGA2[93], etc. It is closely related to the invasion of cancer, and its
expression is a good indicator of prognosis.
1.2.5 The regulation of p62/IMP2 and its role in cancer

y
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Figure 2.

p62/IMP2 gene and its structure

The p62/IMP2 gene is located on 3q27.2, which contains 16 exons and 15 introns. The largest
isoform of p62/IMP2 is 66KD.When exon10 is not transcribed, another 62KD isoform will be
expressed known as p62 (Fig.2). The first intron contains an AT-rich regulatory region. An
oncofetal protein, HMGA2, can bind to this AT-rich region to regulate p62/IMP2 expression [94].
In addition, HMGA2 has recently been reported as a driver of cancer metastasis by inducing
epithelial-mesenchymal transition (EMT) [95]. Therefore, p62/IMP2 overexpression also has a
potential role in promoting cancer metastasis. Besides HMGA2, Airn, a long noncoding RNA
(lncRNA) could bind p62/IMP2 in cardiomyocytes and upregulate the translation of p62/IMP2.
Silencing Airn will decrease expression of p62/IMP2 and reduce the binding ability of p62/IMP2
with its target mRNA [97].
p62/IMP2 was originally identified as an autoantigen in HCC [29], which implied that
p62/IMP2 may play a role in cancer progression. Furthermore, several cancer-associated
p62/IMP2 target mRNAs have been identified, such as CTGF mRNA [96], IGF2 mRNA [72] and
c-myc mRNA [59]. Several studies have reported that p62/IMP2 is involved in carcinogenesis.
p62/IMP2 might be a driver in cancer proliferation. Phosphorylated by mTOR, p62/IMP2 could
stabilize HMGA1 and enhance the expression of IGF2 [101]. By activating the IGF2 / PI3K /
Akt pathway, p62/IMP2 can promote the proliferation, migration, invasion and epithelial to
mesenchymal transition (EMT) of GBM cells [98]. Analysis of a large number of samples shows
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that p62/IMP2 may enhance the proliferation of gallbladder carcinoma by regulating
RAC1-induced ROS generation [99]. In esophageal adenocarcinoma, p62/IMP2 expression is
abnormally increased and is associated with short survival and metastasis [100].
Recently, more and more evidence showed that p62/IMP2 can also enhance the migration
ability of cancer cells and promote cancer metastasis. A cluster of p62/IMP2 targets (LIMS2,
TRIM54, and LAMB2) are considered to be involved in cell migration, cell adhesion, and
cytoskeleton remodeling. These processes are highly related with cancer metastasis [102]. A
recent study from our group found that the overexpressed p62/IMP2 could enhance cell
migration and reduce cell adhesion in breast cancer [96]. Other group also reported that
p62/IMP2 and IMP3 could cooperate to down-regulate progesterone receptor and promote
metastasis in triple-negative breast cancer [103].
Some studies suggest that p62/IMP2 plays an important role in the regulation of EMT in
cancer. One of the mechanisms is that p62/IMP2 can be considered as an indicator of
Wnt/β-catenin signaling pathway in HCC, thereby inducing genomic instability and an invasive
phenotype [104]. In breast cancer, p62/IMP2 could enhance the expression of β-catenin and
promote metastasis [96]. Wnt/β-catenin pathway activation triggers the loss of E-cadherin, plays
a key role in EMT. In sum, overexpressed p62/IMP2 might promote EMT through the activation
of Wnt/β-catenin pathway.
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Chapter 2 Hypothesis and Specific Aims
2.1 Hypothesis
Liver cancer is one of the most common types of cancer and the third leading cause of
cancer related death in worldwide. There are three major subtypes of liver cancer, including
HCC (HCC), cholangiocarcinoma, hepatoblastoma. Among these three types of liver cancer,
HCC is the most common type of primary liver cancers in adults. Most HCC cases are caused by
liver cirrhosis associated with hepatitis B virus or hepatitis C virus infection and excess alcohol
intake. HCC commonly metastasizes to lungs, lymph nodes, adrenal gland and bones, which
leads to poor prognosis for patients.

Insulin-like growth factor 2 mRNA binding protein 2 (p62/IMP2/) was originally reported
as an autoantigen in HCC which belongs to IMPs family. The IMPs family contains three
members: IMP1, p62/IMP2 and IMP3, which share similar protein structure. IMPs are oncofetal
proteins, which are expressed during embryogenesis and lost in most tissues in adults. Therefore,
p62/IMP2 can be used as a potential biomarker for early diagnosis of HCC. It has been reported
that many targets mRNA of p62/IMP2 are highly related with cancer progression, such as c-myc
mRNA, CTGF mRNA, p53 mRNA and RAS mRNA. The cluster of p62/IMP2 targets was
involved in cell migration, cell polarization and cytoskeleton remodeling, all of which could
promote cancer metastasis. Several studies have reported that p62/IMP2 is related to the
metastasis of different types of cancer. However, the mechanism is poorly understood. We
hypotheses that overexpression of p62/IMP2 may play an important role in EMT and
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metastasis of HCC. The proposed study will help us to elucidate the roles of p62/IMP2 in HCC
and provide the basis for novel biomarker development and further design of anti-cancer drug.
2.2 Specific Aims:
Specific Aim 1: To use bioinformatics and in vitro approaches to explore the relevance of
p62/IMP2 to the HCC progression.

Specific Aim 2: To investigate the effect of overexpressed p62/IMP2 on HCC progression.

Specific Aim 3: To explore the effect of overexpressed p62/IMP2 on the molecular mechanism
of HCC carcinogenesis.
2.3 Significance
In worldwide, primary liver cancer is the sixth most common cancer and is the second
leading cause of cancer-related deaths. In China and sub-Saharan Africa, HCC is the most
common cancer among men. Once metastasis occurs, the average survival time of patients with
HCC will be less than 10 months. Therefore, early diagnosis is very important.
p62/IMP2 was first reported as a tumor-associated antigen in HCC. A series of studies have
demonstrated

the abnormal overexpression in HCC cell lines and HCC tissues. Since the

expression of p62/IMP2 is regulated by HMGA2 and closely related to the activation of the
Wnt/β-catenin pathway in HCC, we hypothesize that p62/IMP2 may play an important role in
the metastasis of HCC, but the mechanism remains to be investigated.
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In the present project, firstly we will use bioinformatics approach to analyze and identify
the targets of p62/IMP2, and then conduct in vitro studies to explore the role of p62/IMP2 in
HCC. This project will also focus on the p62/IMP2
pathways and their target genes in the metastasis of HCC. We propose that the in vitro
studies will also provide evidence for a better understanding of HCC metastasis at the molecular
and cellular levels.
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Chapter 3. Materials and Methods
3.1 Data pre-processing
All the original data was downloaded from Gene Expression Omnibus (GEO) for further
pre-processing. R software (version 3.4.3) was used to read and analyze data. The bioconductor
“affy” package was used to adjust the background and normalize the original microarray data.
Probe id was annotated to gene id accordingly. For genes with multiple detecting probes, mean
gene expression values were used in the subsequent analyses.
3.2 Differential expression analysis
Gene expression profile from HCC patients or HCC tissues as well as HCC cell lines were
included. Due to the nature of different type of sample sources, they were analyzed separately.
All samples were separated into two groups, a high expression group and a low expression group
by using the median expression value of p62/IMP2 gene. Bioconductor package “limma” was
used to compare differentially expressed genes (DEGs) in the high and low p62/IMP2 expression
groups. Genes with log2 fold change greater than 1.5 and adjusted p value lower than 0.01 were
considered to be significantly different.
3.3 Gene Ontology (GO) and KEGG annotation of DEGs
R Bioconductor package “clusterProfiler” was used to carry out GO and KEGG annotations
for the DEGs.
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3.4 Cell lines and cell culture
Human HCC cells SNU449 and HepG2 were purchased from ATCC and cultured in RPMI
(GIBCO, Life Technologies, Grand Island, NY, USA). Medium was supplemented with 10%
FBS and 100 units/ml penicillin plus 100ug/ml streptomycin (Thermo Scientific, Waltham, MA,
USA) at 37oC, 5% CO2. When cells were cultured with Wnt/β-catenin inhibitor, 10 μM of
XAV-939 was added into media at 80 percent cell confluence. The cells were collected after 24h
of growth.
3.5 Transfection
To overexpress p62/IMP2, SNU449 cells were transfected using Lipofectamine 2000 (Life
Technologies, Grand Island, NY, USA) in 6-well plates following the manufacturers’ instruction.
800 ng/ml G418 was used to select the transfected cells and to obtain stably transfected clones.
The clones were picked with cloning cylinders (Corning, Tewksbury, MA, USA) and expanded
in 24-well plates.

To knock-down p62/IMP2, co-transfected IMP2 HDR Plasmid (h) and IMP2 CRISPR/Cas9
KO Plasmid (h) (Santa Cruz Biotechnology, TX, USA) with Lipofectamine 3000 (Life
Technologies, Grand Island, NY, USA). Puromycin (1mg/ml) was used to select stable
p62/IMP2 knockout variants. 10 clones for each variant were obtained, and they were expanded
and tested by western blotting.
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3.6 Immunohistochemistry
Immunohistochemistry was performed on a commercially available liver cancer tissue array
(BC03116a, US Biomax, Inc.). Briefly, after deparaffinization with xylene and rehydration with
ethanol, antigen retrieval was performed by microwave heating methods. 2-3 drops of avidin
block solution were applied to the slide to block endogenous biotin activity. After washing,
200μl p62/ IMP2 monoclonal antibody (Cell Signaling Technology, MA, USA) with 1:100
dilution was applied to the cover of every slide and then incubated overnight at 4oC. The slide
was then incubated with polyvalent biotinylated linked goat-anti-rabbit secondary antibody for 1
hour at room temperature. 3'-Diaminobenzidine (DAB) was used for detection. Lastly, the slide
was counterstained with hematoxylin, dehydrated with ethanol, stabilized with xylene and then
processed for imaging.
3.7 Proliferation assay
Cells were seeded at 5x103 cells/well in 96-well plates and grown for 1-5 days. The cell
proliferation was determined by a sulforhodamine (SRB) assay. Briefly, cells were fixed with 10%
(w/v) trichloroacetic acid (TCA) at 4°C for 1 hour, rinsed 5 times with water, and air dried. The
cells were then fixed with 100ul 0.4% (w/v) SRB in acetic acid for 15 minutes. After washing,
the unbound dye was removed by washing five times with 1% acetic acid and the plate was
air-dried. The binding stain was dissolved by 150 ul 10 Mm Tris base each well. Colorimetric
readings were performed in microplate reader at 515nm.
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3.8 Transwell migration assay
Cells were detached from culture plate with 0.25% Trypsin-EDTA solution. After
centrifugation, the cells were resuspended in serum-free medium, and 100 μl of the cell
suspension was added onto the filter of a transwell chamber. The cells were cultured for 16 hours
after carefully adding 600 μl of 10% FBS medium in 24-well plate lower chambers. Cells were
fixed by 3.7% formaldehyde in PBS and then permeabilized by 100% methanol 20 min at room
temperature. Cells were finally stained with 0.1% crystal violet for 15 min and counted under
microscope. After each step, cells were washed twice with PBS.
3.9 Plate clonogenic assay
Cells were seeded onto 6-well plates at 500 cells/well and cultured for 2 weeks with 10%
FBS. The colonies were washed with PBS, fixed with 100% methanol for 15 minutes and stained
with 0.1 % crystal violet for 20 minutes. Colonies with more than 50 cells were counted
manually.
3.10 Wound healing assay
Cell were cultured in 6-well plates and cultured in RPMI medium with 2% FBS. Wound
scratches were made to the all monolayer cells with pipetting tips. The photographs of the wound
scratches were taken every 24 hours. The cell migration levels into the scratch were quantified
using Image J software.
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3.11 Western blotting analysis
Proteins (20 μg/well) were separated on 10% SDS-PAGE gels and transferred onto
nitrocellulose membrane. Blocking in 5% no fat milk TBST buffer for 1 hour in room
temperature. Membranes were incubated at 4°C in TBST with primary antibodies overnight, then
in TBST with secondary antibody at room temperature for 1 hour. Finally, an enhanced
chemilluminescence visualization kit (Thermo Fisher Scientific, MA, USA) was used to
visualize the staining bands. Protein expression was detected by western blotting with rabbit
monoclonal antibodies: p62/IMP2, β-catenin, Wnt3a, Wnt 5a/b, GSK3β, Snail, N-cadherin,
GAPDH (Cell Signaling Technology, MA, USA); and mouse antibodies: E-cadherin (Cell
Signaling Technology, MA, USA). Primary antibodies were detected with goat anti-mouse IgG
(HPR conjugate) or anti-rabbit IgG (HPR conjugate). The membranes were finally scanned by
Invitrogen iBright Imaging System (Thermo Fisher Scientific, MA, USA).
3.12 Immunofluorescence
Cells were seeded onto 8-chamber culture slides and grown for 24 hours fixed with 100%
methanol and 100% acetone at -20°C. The cells were subsequently treated with β-catenin
monoclonal antibody (Cell Signaling Technology, MA, USA) and incubated with Alexa Flour
488 conjugate secondary antibodies. Mounting medium containing DAPI was then added.
Confocal fluorescence images were acquired with a laser scanning microscope (LSM 700; Zeiss,
New York, NY, USA).
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3.13 Phosphoproteome assay
The Wnt Pathway Phospho Antibody Array (PNT227) was conducted by Full Moon
BioSystem Inc, which contains 227 site-specific and phospho-specific antibodies. SNU449 cells,
HepG2 cells and their transfected variants were harvested as whole-cell lysates and transferred to
Full Moon Biosystem Inc in dry ice. Further, proteins were purified, labeled with biotin and
placed on the blocked microarray with coupling solution. 0.1% Cy3-Streptavidin solution was
used to detect conjugation-labeled proteins. The phosphorylation degree of a site was represented
by the ratio of phosphorylation/unphosphorylation.
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Chapter 4. p62/IMP2 is Highly Associated with Hepatocellular Carcinoma
4.1 Overview
The family of insulin- like growth factor 2 mRNA binding proteins (IMPs) contains three
members: IMP1, p62/IMP2 and IMP3. All these proteins are oncofetal proteins, expressed
during embryogenesis and lost in most tissues in adults. However, IMPs were found to be
overexpressed in various cancers. In this project, we will focus on p62/IMP2 and explore its role
in HCC progression. In chapter 4, the association between p62/IMP2 and HCC will be
investigated.
4.2 Rationale, experimental design and alternative approach
Specific Aim 1: To use bioinformatics and in vitro approaches to explore the relevance of
p62/IMP2 to the HCC progression.
4.2.1 Rationale
The high frequency of anti-p62/IMP2 autoantibody occurrence in the serum samples from
various types of cancer patients implies that p62/IMP2 may play a role in cancer progression.
Several cancer-associated p62/IMP2 target mRNAs have been identified. They include CCN2
mRNA (15), IGF2 mRNA (7) and c-Myc mRNA. In previous study, our group has demonstrated
that p62/IMP2 is overexpressed in breast cancer. However, we still know very little about the
role of p62/IMP2 in the development of HCC.

Many studies have demonstrated that the occurrence of HCC is mainly due to the gene
mutations, abnormalities of proteins and the change of cell metabolism. Differentially expressed
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genes may be directly or indirectly related to the occurrence and susceptibility of cancer. The
significance of detecting these differentially expressed genes lies in the ability to reveal the
mechanism of cancer development from the gene level and to better explore the methods for
cancer treatment. The formation of tumors is a long-term and complex process that requires the
mutations of multiple genes at multiple stages, including changes in tumor suppressor genes and
oncogenes, and dysregulation of normal genes. In this specific aim, we plan to find HCC related
datasets in Gene Omnibus (GEO) database, and will perform a preliminary analysis of the role of
p62/IMP2 in liver cancer and possible regulatory pathways through differential expression
analysis.
4.2.2 Experimental Design & Methods:
1）Analysis of p62/IMP2 expression in HCC by in vitro methods: to examine the expression of
p62/IMP2 in HCC tissues, a multiple HCC tissues microarray was used for performing
immunohistochemistry (IHC). The microarray contains 40 tumor tissues with detailed clinical
information and 30 non-tumor tissues including tumor adjacent tissues and healthy tissues as
control. The microarray was performed by IHC with p62/IMP2 antibody and the results were
analyzed between tumor and non-tumor tissues. The expression of p62/IMP2 in normal liver cell
lines (L02) and HCC cell lines (HepG2, SNU449, Hep3b, Huh7 and SMMC7721) was detected
by western blotting analysis. We subsequently compared the expression differences of p62/IMP2
in normal liver cells, highly differentiated HCC cells and poorly differentiated HCC cells. In
addition, we examined the frequency of autoantibody against p62/IMP2 in sera from HCC
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patients. A total of 160 HCC sera and 90 normal human sera as controls were obtained from the
serum bank of Cancer Autoimmunity and Epidemiology Research Laboratory at the University
of Texas, El Paso. Recombinant p62/IMP2 protein was purified and ELISA was used to screen
the sera with p62/IMP2 autoantibody.

2) Analysis of p62/IMP2 expression in HCC by bioinformatics approaches: three HCC gene
expression datasets (accession numbers GSE 25097, GSE36376, GSE 14520) were downloaded
from GEO, the p62/IMP2 mRNA expression data was analyzed in normal tissue group (only in
GSE 25097), tumor adjacent tissue group and HCC tissue group. Subsequently, high and low
p62/IMP2 expression groups were set up based on the median expression of p62/IMP2 to obtain
the DEG profile. Based on the DEG profile, GO analysis, KEGG analysis and FunRich
enrichment analysis were performed with R (version 3.4.3) and Funrich (version 3.1.3) software.
4.2.3 Potential problems & alternative approaches:
Due to the high prevalence of autoanbodies against p62/IMP2 was detected in HCC patients,
we expect the overexpression of p62/IMP2 is highly related to the progression of HCC. However,
the overexpression of proteins is not the only reason to stimulate the immune system to produce
autoantibodies. Other factors such as protein structure alternation and chronic inflammation can
also result in autoantibodies production. Otherwise, the reliable results of IHC and western
blotting analysis are relied on the high sensitivity and specificity of the antibodies. In this project,
bioinformatics approaches are performed to provide support for in vitro studies.
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4.3 Results
4.3.1 In vitro studies showed that p62/IMP2 is overexpressed in HCC.
To examine the expression level of p62/IMP2 in HCC tissues, we performed
immunohistochemistry (IHC) analysis on a tissue array including 40 HCC tissues and 30 normal
liver tissues. The expression of p62/IMP2 was scored by the immune-staining intensity and
positive immune-staining cell area. p62/IMP2 protein is overexpressed in human HCC tissues
compared with normal human liver tissues (score= 10.30, n=40 vs. score =5.23, n=30, p<0.05)
(Table 2). The color scores between HCC tissues and normal tissues were significantly different,
while the area score results were similar. The representative examples of weak p62/IMP2
staining pattern of adjacent normal tissue and strong p62/IMP2 staining pattern of HCC tissue is
shown in Figure 3. In addition, western blotting analysis was performed to examine p62/IMP2
protein expression in the non-tumorigenic liver cell line L02 and three HCC cell lines. p62/IMP2
are overexpressed in all the HCC cell lines; in contrast, L02 cells showed a relatively low
expression level of p62/IMP2. Meanwhile, p62/IMP2 was overexpressed in well-differentiated
cell lines (HepG2, Hep3b and Huh7) compared to the poorly differentiated cell lines (SNU449)
(Fig.5). To detect the anti-p62/IMP2 autoantibody in HCC patients, the p62/IMP2 recombinant
protein was purified and used as coating antigen in ELISA for the detection of 160 sera from
HCC patients and 89 normal controls (Fig. 4 & Table 3).

The average OD value of

anti-p62/IMP2 autoantibody in HCC sera is significant higher than that in normal controls. The
prevalence of anti-p62/IMP2 autoantibody in HCC sera is 18.1%, which is significantly higher
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than that in normal control sera (2.2%), while using Mean+3SD of normal group OD value as the
cut-off value.
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Figure 3. Immunohistochemical staining of p62 in Liver cancer tissue and adjacent normal
tissue slides.

A. Positive stain pattern of p62 in representative liver cancer tissue. B. Weak stain pattern of p62
in representative adjacent normal tissue Positive stain pattern of p62 in representative liver
cancer tissue. (x100 and x400 magnification).
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Figure 4. Distribution of autoantibodies against p62/IMP2 in HCC sera and normal human
sera.

The distribution of antibody titers is indicated as optical density (OD) obtained from ELISA.
HCC: sera from HCC patients. NHS: normal human sera.
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Figure 5. The expression of p62/IMP2 in normal liver cell line L02 and HCC cell lines.

Compare to L02, p62 is slightly overexpressed in SNU449 and SMMC7721 cells and highly
overexpressed in HepG2, Huh7 and Hep3b cells.
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Table 2.

Expression of p62/IMP2 in HCC tissues and adjacent normal tissues.

Type of tissues
Tumor tissues
Stage I tumor tissues
Stage II tumor
tissues
Stage III tumor
tissues
Normal tissues

IHC score
Sample Quantity Color
Area
Final score
40
2.823*
3.68
10.30*
4
2.50*
3.75
9.00*
13

2.85*

3.54

10.15*

23

2.87*

3.74

10.61*

30

1.5

3.67

5.23

*p<0.05, compared with normal group. (one-way ANOVA)
The staining of p62/IMP2 was evaluated by a four-level scoring system for color and area. The
final score is the product of color and area score. Here we show the average number of samples.
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Table 3. Frequency of autoantibody response to p62/IMP2 in sera from HCC patients
(HCC) and normal human sera (NHS)
Group
HCC
NHS
Total

Positive(%)
29/160 (18.1%)*
2/89 (2.2%)
31

Negative (%)
131/160 (81.9%)
87/89 (97.8%)
218

Total
160
89
249

Cutoff value: Mean+3SD of normal group;
HCC group vs Normal group: * p<0.01;
HCC: sera from HCC patients; NHS: sera from normal human.
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4.3.2 Bioinformatics studies indicated that p62/IMP2 is highly associated with HCC
progression.
We investigated p62/IMP2 mRNA expression in a large cohort of HCC patients from the
GEO database (accession numbers GSE 25097, GSE36376, GSE 14520). Compared with
adjacent tissues of HCC and normal liver tissues from healthy people, p62/IMP2 gene expression
in HCC tissues was significantly upregulated in all the three datasets. p62/IMP2 gene expression
did not show a distinct difference between normal liver tissues and adjacent tissues in GSE
25097 (Fig. 6). To acquire the DEG profile in HCC, we set up a p62/IMP2 high expression group
and a p62/IMP2 low expression group based on the median in GSE 14520 and processed them in
R software. Totally 900 DEGs was selected and further used for GO analysis. The cellular
component analysis demonstrated that most of the proteins expressed by DEGs are located in the
cell membrane and cytoplasm, which might be an indirect evidence that p62/IMP2 is involved in
the regulation of cell migration (Fig. 7). In Funrich enrichment biological pathway analysis as
well as cellular component analysis, our data supported GO enrichment analysis: 9.9% DEGs
were figured out related to EMT (p<0.01) and the DEGs are mainly distributed in cell
membranes and collagens (Fig.8). Therefore, we select 20 DEGs related with EMT and analyzed
their interaction genes and we found that a lot of interaction genes are involved in Wnt signaling
pathway (Fig. 9).
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Figure 6. mRNA expression of p62/IMP2 in tumor tissues and their controls in datasets
GSE 25097, GSE 36376 and GSE 14520.

Y axis showed the log2 fold change of the p62/IMP2 gene expression. In all the three datasets,
p62/IMP2 mRNA expression in HCC tissues is significantly higher than adjacent tumor tissues.
*p<0.05, **p<0.01.
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Figure 7. Gene Ontology analysis was performed between p62/IMP2 high expression group
and low expression group.

We listed 15 most enriched terms in molecular function and biological process analysis and 10
most enriched terms in cellular components analysis.
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Figure 8. The FunRich enrichment analysis of Biological pathway and Cellular component for 900 DEGs.

The enrichment analyses were performed with FunRich 3.1.3 software.
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Figure 9. Gene Interaction analysis of metastasis related DEGs.

The selected metastasis related DEGs are shown as red and their directly interacted gene are
shown as green.
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Chapter 5. The Effect of p62/IMP 2 in HCC Progression
5.1 Overview
In chapter 4, we indicated that overexpression of p62/IMP2 is widely existed in HCC.
Hence, we will discuss the role of p62/IMP2 in HCC progression based on it. In the development
of cancer, cancer cells will display many new features that are different from ordinary cells, for
instance, anti-apoptosis ability, EMT, higher proliferation ability and motility. In chapter 5, we
will focus on the functional study of p62/IMP2 and perform a series of in vitro studies. Our
results in this chapter will reveal the function of p62/IMP2 in HCC and guide us to the next step,
the molecular signaling research.
5.2 Rationale, experimental design and alternative approach
Specific aim 2: To investigate the role of p62/IMP2 on HCC progression
5.2.1 Rationale:
In specific aim 1, we explored the expression of p62/IMP2 in HCC and its potential
function by using bioinformatics methods. In specific aim 2, we will establish in vitro models by
knockout p62/IMP2 in HCC cell lines to further study the function of p62/IMP2 in HCC.
Although we first discovered autoantibodies to p62/IMP2 in HCC, we know very little about the
role of p62/IMP2 in liver cancer. Our group showed that p62/IMP can enhance migration ability
and reduce cell adhesion in breast cancer. There are also other studies that clarify that p62/IMP2
plays a role in cancer metastasis. For example, p62/IMP2 has been shown to be closely related to
the metastasis of breast and esophageal adenocarcinomas. By activating the IGF2 / PI3K / Akt
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pathway, p62/IMP2 can promote GBM cell proliferation, migration, invasion and
epithelial-mesenchymal transition (EMT) (98). In addition, several mRNA targets of p62/IMP2
such as CTGF mRNA, IGF2 mRNA and c-myc mRNA have been shown involved in the
proliferation of cancer cells. Therefore, in this chapter, we will concentrate on the effect of
overexpressed p62/IMP2 on proliferation and migration ability in HCC cell lines.
5.2.2 Experimental Design & Methods:
We have known that p62/IMP2 is overexpressed in most of HCC cell lines in chapter 4. To
explore the changes in cell function induced by overexpression of p62/IMP2, our strategy is to
overexpress or knockdown p62/IMP2 in HCC cells by transfecting Crisper/Cas 9 plasmids. After
establishing stable transfected HCC cell line variants, we will conduct a series of functional
studies.

1) The effect of overexpressed p62/IMP2 on proliferation ability. We designed three
experiments to examine the cell proliferation ability. The first one is proliferation assay. The
sulforhodamine B (Srb) will be used for checking proliferation ability between wild type HCC
cells and the transfected variants. Compared to other competitor methods such as MTT assay, it
is more reliable and repeatable. We also performed the cell cycle assay by flow cytometry as the
second one. It visually reflects the proportion of cells at each stage. When the cells in the G2 and
S phases are increased, we believe that the proliferation of the cell line is enhanced. Another test
we used is plate clonogenic assay. It not only reflects the proliferative capacity of cells, but also
reflects the independent survival ability of cells.
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2) The effect of overexpressed p62/IMP2 on cell migration ability. We performed wound healing
assay and transwell migration assay to check the cell migration ability. In Wound healing assay,
cells were cultured in 6-well plates and the wound scratches were made to the all monolayer cells
with pipetting tips. The photographs of the wound scratches were taken every 24 hours so we can
compare the cell migration ability between HCC cell variants. Transwell migration assay is
another well-established experiment that can examine the cell migration ability. Counted cells
were cultured in a chamber in 24-well plates overnight, the number of cells that can pass the
membrane shows their migration ability.
5.2.4 Potential problems & alternative approaches:
We expect that a series of in vitro experiments, such as the wound healing assay, transwell
migration assay, will support our hypothesis that the overexpression of p62/IMP2 to promote the
cell migration ability of HCC cells. Our potential problem is that although different cancers
exhibit similar properties, the underlying mechanisms of mutations between different cancers are
not the same. Therefore, our hypothesis based on past breast cancer research does not necessarily
occur in HCC. The molecular mechanism of cancer is very complicated. Although the target of
IMP2 is related to the migration ability and proliferation ability of cells, the influence of IMP2
overexpression on cells is unknown. Another potential problem is that different HCC cell lines
contain different genetic background. A single cell line can only represent part of the HCC
genetics, so we will select two or more representative cell lines for experiments.
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5.3 Results
5.3.1 Establishment of stable p62/IMP2 knockdown variants in HepG2, SNU449, and
p62/IMP2 overexpression variants in SNU449 cell lines
We discussed the expression of p62/IMP2 in multiple HCC cell lines in chapter 4. Among
them, HepG2 is highly differentiated from Caucasians, while SNU449 is from Asians with low
degree of differentiation and strong invasion ability. Because they represent diverse genotypes of
HCC, we want to explore whether p62/IMP2 plays a similar role in these two cell lines.

To explore the biological roles of p62/IMP2 in HCC progression, p62/IMP2 was knockout
in two p62/IMP2 positive HCC cell lines (SNU449, HepG2). Due to the low expression level of
p62/IMP2 in SNU449, we performed the transfection experiment to overexpress p62/IMP2 in
this cell line (Fig. 10).
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Figure 10. Verification of p62/IMP2 overexpression and knockout cell line with western
blotting analysis.

A. Western blotting result of p62/IMP2 knockout in HepG2 cell line. B. Western blotting result
of p62/IMP2 overexpression and knockout in SNU449 cell line.
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5.3.2 p62/IMP2 does not significantly promote cell proliferation but reduces cell population
dependence and enhances colony formation.
All the generated variants were tracked for 5 days in a proliferation assay to examine their
relative growth rate. However, regardless of whether p62 was overexpressed or knocked down,
we did not observe a consistent impact on the proliferation in either cell line (Fig .11). The cell
cycle distribution of each variant was measured by flow cytometry. The results support our
proliferation assay results in that the cell cycles profiles were not significantly altered by the
transfections. The only exception to this was for the cell ratio in the G2/M phase of IMP2
knockdown cells decreased 7%-9%, compared with their corresponding wild type parental cells
(Fig 12). Surprisingly, in a clonogenic assay, p62/IMP2 overexpressing cells showed a higher
colony formation rate in both cell lines (Fig. 13). At the same time, the clone formation rate of
SNU449 IMP2 knockdown cells had a moderate increase as well. Clone formation rate reflects
two important features: cell population dependence, and proliferation ability. Considering that
overexpression or knocked out p62/IMP2 did not alter the proliferation ability in both HCC cell
lines, our results indicated that the change of p62/IMP2 expression enhanced the ability of
growing without population dependence.
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Figure 11. Overexpression of p62/IMP2 does not promote HCC cell proliferation ability.

A. Growth curve of the cell proliferation assay in SNU449. B Growth curve of the cell
proliferation assay in HepG2 cells. SNU449 IMP2+ vs SNU449 IMP2-: #p<0.05; SNU449(WT)
vs SNU449(IMP-): *p<0.05 (two-way ANOVA, n=3HepG2(WT) vs HepG2(IMP-): *p<0.05
(multiple t-test, n=3).
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Figure 12. Cell cycle of p62/IMP2 variants tested by flow cytometer.

A. Cell cycle of SNU449 variants. B. Cell cycle of HepG2 variants. The expression of p62/IMP2
does not affect the cell cycle in either cell lines.
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Figure 13. plate clonogenic assay p62/IMP2 variants from two HCC cell lines.

A. Both overexpression and knock down of p62/IMP2 could promote colony formation ability in
SNU449 cells. B. Knockdown of p62/IMP2 reduce colony formation ability in HepG2. *p<0.05
(one-way ANOVA, n=3).
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5.3.3 Overexpression of p62/IMP2 promotes cell migration in HCC
A cellular component of GO classification showed that most proteins expressed by DEGs
are expressed in the cell membrane and cytoplasm (Fig. 7). This might be the indirect evidence
that p62/IMP2 is involved in the regulation of cell migration. We performed two in vitro assays,
a wound healing assay and a transwell migration assay, to investigate the cell migration
properties. Although the migration rate of hepG2 cells is significantly lower than SNU449 cells,
both of assays showed consistent results that overexpressed p62/IMP2 can promote HCC cell
migration in vitro. Overexpression of p62/IMP2 in HCC cells increased ‘wound’ closure by 40%
to 50% compared to wild-type cells, which also significantly increased the number of
transmembrane cells in the transwell migration assay (Fig. 14&15).
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Figure 14. The wound healing assay showed that overexpression of p62/IMP2 promotes cell
migration in HCC.

A. Overexpression of p62/IMP2 can promote cell migration ability in SNU449. B.
Overexpressed p62/IMP2 enhances cell migration ability in HepG2. SNU449 IMP2+ vs SNU449
IMP2-: #p<0.05; SNU449(WT) vs SNU449(IMP-): *p<0.05; SNU449 IMP2+ vs SNU449 WT:
△p<0.05 (two-way ANOVA, n=3). *P < 0.05 (t-test, n=3).
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Figure 15. The transwell migration assay in p62/IMP2 variants from two HCC cell lines.

A&B. Overexpressed p62/IMP2 can increase the trans-membrane cell number in both SNU449
and HepG2 cell variants. The image of transwell migration assay for p62/IMP2 variants at
random area under 100X microscope. * p<0.05, ** P<0.01 (One-way ANOVA and t-test, n=3).
Values represented mean ±SEM of three independent measurements.
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Chapter 6. Identification the Effect of Overexpressed p62/IMP2 on the
Molecular Mechanism of HCC Carcinogenesis
6.1 Overview
In chapter 5, we demonstrated that overexpressed p62/IMP2 can enhance the migration
ability of HCC cells. However, we still know very little about the molecular mechanism of this
phenomenon. Many studies have shown that the classical Wnt signaling pathway plays a very
important role in the development of HCC and 40%-70% of the HCC cells have β-catenin
aggregation in the nucleus, which is also result from Wnt signaling activation. At the same time,
activation of the Wnt pathway is involved in the process of EMT, playing an important role in
the metastasis of cancer cells. In this chapter, we will explore the molecular mechanisms of
overexpression of p62/IMP2 in cancer metastasis and our understanding of the occurrence of
p62/IMP2 autoantibodies will go a step further.
6.2 Rationale, experimental design and alternative approach
Specific aim 3: To explore the effect of overexpressed p62/IMP2 on the molecular mechanism
of HCC carcinogenesis.
6.2.1 Rationale
The emergence of HCC is a multi-factor, multi-gene involved, multi-step process. Its 5-year
survival rate is not more than 50%, and its treatment is still based on local treatment and
systemic therapy [31]. Radiotherapy, Chemotherapy, targeted therapy, and surgery are the
mainly treatment strategies, but HCC is not sensitive to radiotherapy and chemotherapy, so the
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research on targeted therapy for the pathogenesis of HCC is more urgent. Wnt signaling pathway
plays an important role in the occurrence, development, metastasis and prognosis of HCC. In
HCC cases, β-catenin gene mutations accounted for 8%-30%, APC and Axin protein gene
mutations and loss of function accounted for 1%-3% and 8%-15%, respectively [105]. However,
the mutation mechanism of β-catenin gene is quite different from others. Interestingly, studies
have shown that the mutation of β-catenin gene appears relatively late in the development and
progression of HCC, while the accumulation of β-catenin protein in the nucleus occurs in the
early stage of HCC.
6.2.2 Experimental Design & Methods:
The approach we used to identify the targets of p62/IMP2 is DEGs analysis by using a
metastasis-related gene profiling. A metastasis gene list was downloaded from QIAGEN’s
website, which contains 206 key metastasis related genes. The mRNAs of these genes were
investigated in high and low p62/IMP2 expression samples as we used in Chapter 4. The DEGs
would be the potential targets we will investigate in next step. For potential target proteins and
the pathways in which they are located, we will use western blotting analysis and
immunofluorescence for further validation. Western blotting analysis and immunofluorescence
assay can quantitatively analyze the expression of the protein, and immunofluorescence assay
can also show the location of protein expression. After that, we will use the pathway inhibitor to
verify the previous experiment. In the regulation of pathways, changes in the phosphorylation
level of proteins are also important aspects. Hence, a Wnt Pathway Phospho Antibody Array
which contains 227 site-specific and phospho-specific antibodies was used to check the alteration
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of phosphorylation degree between each HCC cell variants. Through it we can understand the
more comprehensive picture of the changes caused by p62/IMP2 overexpression.

6.2.3 Potential problems & alternative approaches
We expect overexpressed p62/IMP2 can activate the Wnt/ β-catenin pathway, and activation
of the Wnt/β-catenin pathway is responsible for the increased migration of HCC cells. The
potential problem is that the impact of overexpression of p62/IMP2 is unknown, and there may
be a plenty of mRNA targets of p62/IMP2. Therefore, Wnt/β-catenin pathway may not be the
only signaling pathway that regulates cell migration. As a way to solve the problem, we will use
Wnt pathway inhibitors to verify our results.

6.3 Results
6.3.1 Overexpression of p62/IMP2 can induce EMT through the Wnt/ β-catenin pathway
To better understand how the change of p62/IMP2 can regulate cell migration in HCC cells,
we divided the HCC gene expression profile GSE 14520 into 2 groups based on the median of
p62/IMP2

expression

and performed differential

expression

gene analysis

with

a

metastasis-related gene list (QIAGEN). One of the top genes we selected was β-catenin (Based
on LogFC+ adj. p value) because we considered it as candidate of the targets of p62/IMP2
(Fig.16). It is involved in the regulation of Wnt signaling. Since Wnt/β-catenin pathway plays an
essential role in the process of EMT and cancer metastasis, we examined the expression of
β-catenin by immunofluorescence (Fig. 18). The results indicated that the expression of
β-catenin was significantly enhanced when p62/IMP2 was overexpressed and decreased in
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p62/IMP2 knocked out variants (Fig.18). HepG2 and SNU449 cell lines were reported having
activated Wnt/β-catenin signaling due to the mutations in their CTNNB1 gene. Due to this, we
hypothesized that the translocation of β-catenin into nucleus can be observed in both cell lines
and their variants. However, we only observed a stronger nuclear expression pattern of β-catenin
in the p62/IMP2 overexpressed cells. When p62/IMP2 is expressed in low quantities, β-catenin
exhibited a more cytoplasmic expression pattern. The change of β-catenin expression influenced
by p62/IMP2 was confirmed in western blotting analysis. In addition, we tested the expression of
several key proteins that are involved in the regulation of Wnt/β-catenin signaling pathway and
EMT. In general, the protein expression of Wnt5a/b, Wnt3a, and snail presented a positive
correlation with the expression of p62/IMP2, while GSK3β and E-cadherin emerged a negative
correlation with the expression of p62/IMP2. However, there are some exceptions in the results
of western blotting analysis: For example, Wnt5a/b was lost in the HepG2 cell line. In contrast, it
was overexpressed in SNU449 IMP2 knocked down cells (Fig.17).
We further explored whether inhibition of β-catenin expression could attenuate migration
ability of HCC cells. The expression of β-catenin in wild type of HepG2 and SNU449 cells is
reduced by around 30% to 60%, after being cultured in 10μM Wnt/β-catenin signaling inhibitor
XAV939 medium. (Fig.19&20). Consequently, in vitro Wound healing assay provided evidence
that inhibition of β-catenin can suppress the migration ability in wildtype and p62/IMP2
overexpressed HCC cells, whereas no significant change was observed in p62/IMP2 knockdown
HCC cells (Fig. 21).
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Figure 16. DEGs analysis with a metastasis related gene list.

The -log10 (adj. p value) and LogFC (log 2 conversion of the fold change) between p62/IMP2
high expression group and p62/IMP2 low expression group was shown in a scatter diagram. The
gene of β-catenin (CTNNB1) is selected for future research.
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Figure 17. Western blotting analysis of Wnt/ β-catenin signaling and EMT related proteins.
Overexpressed p62/IMP2 enhanced the Wnt signaling and the expression of β-catenin, inhibited
the expression of GSK3b and finally triggered the loss of E-cadherin.
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Figure 18. Immunofluorescence staining of β-catenin in SNU449 and HepG2 cells.
Clearly nuclear expression pattern of β-catenin was shown when p62/IMP2 expressed high. Cell
nucleuses were stained with DAPI (blue). In contrast, knockdown of p62/IMP2 significantly
reduced the expression of β-catenin.
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Figure 19. Western blotting analysis showed β-catenin expression was significantly
inhibited by XAV939.
In all SNU 449 and HepG2 variants, 10 μM XAV939 can significantly inhibit the expression of
β-catenin.
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Figure 20. Immunofluorescence showed β-catenin expression was significantly inhibited by
XAV939.
In both SNU449 and HepG2 cells, 10 μM XAV939 can significantly inhibit the expression of
β-catenin.
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Figure 21. Inhibition of Wnt/ β-catenin signaling can reduce migration ability in HCC cell
lines.

XAV939 repressed migration ability in p62/IMP2 overexpression and wildtype HCC cells. In
contrast, XAV 939 did not show inhibition of migration ability in IMP2 knockdown cells.
Wound scratch image was taken each 24h, the wound healing area was quantified and each point
(48h per time in HepG2 line). *p<0.05 (Two-way ANOVA, n=3)
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6.3.2 IMP2 can regulate the phosphorylation of Wnt/β-catenin signaling
IMP2 was reported to be involved in the post-translational modification of their targets,
including phosphorylation [106]. Therefore, we performed a phosphoproteome analysis by
phospho explorer antibody microarrays and then characterized and compared phos/unphos
(phosphorylation/unphosphorylation) ratio between transfected and wild type cell lines. There
are 93 well-characterized phospho-specific antibodies in the microarray, and we selected 23 Wnt
related phosphorylation sites from them. Interestingly, the pattern of phosphorylation is diverse
in each group. In general, overexpression of p62/IMP2 enhanced canonical Wnt signaling in both
SNU449 and HepG2 cell lines, but the pattern of affected phosphorylation sites was different.
In SNU449, the change of p62/IMP2 mainly regulates the cytoplasmic phosphorylation sites
associated with β-catenin degradation, such as β-catenin Y654, T41/S45, S37 and APC S2054.
Among them, phosphorylation ratio of β-catenin S37 increased by 77 percent in p62/IMP2
knocked down cells, while it decreased 19 percent in p62/IMP2 overexpressed cells, which
promoted the degradation of β-catenin induced by GSK3b and supported our western blot results
in Fig.17. In contrast, change of p62/IMP2 in HepG2 primarily regulates the Wnt signaling
receptor-associated phosphorylation site on the cell membrane (Src Y529, S75 and CKIα Y321)
(Fig 24). At the same time, in SNU449 cells, the expression of p62/IMP2 was negatively
correlated with the phosphorylation site that activated non-canonical Wnt signaling (Fig. 22&23),
whereas we did not find a correlation between the expression level of p62/IMP2 and the
phosphorylation level of non-canonical Wnt signaling in HepG2 cells (Fig. 24).
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Figure 22. Overexpression of p62/IMP2 enhanced both Canonical Wnt and non-canonical
Wnt signaling.

The change of Phosphorylation rate (phosphorylated protein/phosphorylated protein) between
SNU449 IMP+ and SNU449 WT cells was tested by a phosphoproteome array which screened
the total cell lysates. The gray area was defined as “no change area” (≥83%/≤120%). The
induction/reduction of phosphorylation sites was shown with color when their bar is out of the
gray area boundaries.
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Figure 23. Knockdown of p62/IMP2 reduces the canonical and non-canonical Wnt
signaling.

The change of Phosphorylation rate (phosphorylated protein/phosphorylated protein) between
SNU449 IMP knockdown and SNU449 WT cells was tested by a phosphoproteome array which
screened the total cell lysates. The gray area was defined as “no change area” (≥83%/≤120%).
The induction/reduction of phosphorylation sites was shown with color when their bar is out of
the gray area boundaries.
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Figure 24. Knockdown p62/IMP2 inhibit canonical Wnt signaling in HepG2 cells.

The change of Phosphorylation rate (phosphorylated protein/phosphorylated protein) between
HepG2 IMP2 knockdown and HepG2 WT cells was tested by a phosphoproteome array which
screened the total cell lysates. The gray area was defined as “no change area” (≥83%/≤120%).
The induction/reduction of phosphorylation sites was shown with color when their bar is out of
the gray area boundaries.
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Chapter 7. Discussion and Future Direction
7.1 Discussion
In 1999, p62/IMP2 was first identified as a TAA in HCC [29]. Our previous work
showed that a high frequency of its autoantibodies can be detected in sera from HCC patients,
which suggests that p62/IMP2 can be used as a biomarker of HCC [107]. Nevertheless, the
mechanism underlying the production of p62/IMP2 autoantibodies in HCC remains to be
explored. Previous studies revealed that most TAAs are non-mutated and but overexpressed in
tumor tissues. Autoantibodies against these TAAs are produced when the antigenic peptides
presented on human leukocyte antigen (HLA) class I molecules exceeds the TCR threshold
which is required for CD4+ T cell activation [108].

In this study, we provided evidence for the

hypothesis: p62/IMP2 is aberrantly overexpressed in both HCC tissues and cell lines, and our
IHC results showed that the expression of p62/IMP2 reached a high level in the early stage of
cancer, which is consistent with a previous study showing that autoantibodies can be detected
early in HCC [109]. Considering that the overall survival time is less than 1 year for late stage
HCC patients (based on the BCLC staging system), early diagnosis is very

important for

improving the prognosis of patients. In summary, using autoantibodies against a panel of
cancer-associated antigens including p62/IMP2 may be a potential approach

for future

diagnosis of early HCC [107].

As much as 90 percent of cancer related deaths can be attributed to metastasis [47]. Through
the establishment of stable p62/IMP2 overexpressed and knocked down cell lines, we found that
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aberrantly expressed p62/IMP2 can regulate the cell migration ability of HCC cells via
regulating the expression of β-catenin. β-catenin is known to play a key role in
cadherin-mediated cell adhesion system. Without Wnt signaling cascade activation, the
β-catenin-α-catenin complex bridge the cadherin to the actin cytoskeleton physically in the
cytoplasm [65]. Once Wnt binds with Fz and LPR5/6, the Wnt/β-catenin signaling pathway
activates and allows β-catenin to accumulate in the cytoplasm in order to finally translocate into
the nucleus. β-catenin in p62/IMP2 overexpressed cells showed a clear nuclear expression
pattern. On the contrary, β-catenin is localized in the cytoplasm of HepG2 p62/IMP2 knockdown,
SNU449 WT, and SNU449 p62/IMP2 knockdown cells. At the same time, a canonical Wnt
ligand, called Wnt3a, was expressed only in p62/IMP2 overexpressed cells, which implies that
Wnt/β-catenin signaling is enhanced by the overexpression of p62/IMP2. In the activated
Wnt/β-catenin signaling pathway, reduction of GSK3β reduces the phosphorylation of Snail,
thereby enhancing its stability [110], inhibiting the expression of E-cadherin, and ultimately,
inducing the occurrence of EMT.
Surprisingly, although the expression of β-catenin was intensely repressed, the p62/IMP2
knockdown SNU449 cells also expressed higher colony formation ability than SNU449 wild
type cells. Accordingly, we examined the noncanonical Wnt signaling pathway, which is
β-catenin independent and can antagonize canonical Wnt signaling in HCC [111]. Wnt receptor
Frizzled 2 and its ligand Wnt5a/b were found to be elevated in various cancers that also promote
proliferation and cell migration ability [112]. HCC cell lines express Wnt ligands diversely.
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Briefly, well-differentiated cell lines such as HepG2 mainly express Wnt3a, whereas poorly
differentiated cell lines like SNU449 mainly secrete Wnt5a/b [113]. In the scenario of the
sharply down regulation of β-catenin SNU449 knockdown cells, Wnt5a/b may be oppositely
upregulated and thus trigger the process of proliferation and EMT. P62/IMP2 is the only IMP
family member which was reported existed in adult liver tissues [71]. Our study suggests that the
trace of p62/IMP2 expression is important to maintain the normal function in hepatocytes.
The protein activity, stability that involved in Wnt signaling were regulated by
phosphorylation status at multiple steps [114].

In this study, we show that the manipulation of

the expression of p62/IMP2 triggers a series of changes in the phosphorylation of various Wnt
pathway proteins. In the absence of a Wnt stimulus, free β-catenin in cytoplasm will be degraded
by a “destruction complex” including APC, GSK3, Axin, and CK1 [115]. In SNU449 p62/IMP2
knockdown cells, CK1α-mediated phosphorylation of ser45 on β-catenin was elevated, which
allowed β-catenin to enter the “destruction complex” and specifically interact with Axin [116].
Subsequently, with the dramatic increase of GSK3-mediated phosphorylation of Ser-37 and
Thr-41, β-catenin binds with APC, stays in this complex, and is eventually degraded [117].
Simultaneously, the affinity for cadherins is strengthened with the reduction of Tyr 654
phosphorylation on β-catenin [118]. Decreased phosphorylation of APC at ser 2054 can facilitate
the APC to be transported to the nucleus [119]. Besides that，the AKT-mediated phosphorylation
of GSK3α at ser 21 significantly inhibits the activity of itself [120] (Fig. 23). In summary, all of
these changes in phosphorylation strengthens the stability of β-catenin and enhances the
Wnt/β-catenin signaling.
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In HepG2 cells, the phosphorylation regulated by p62/IMP2 showed a different pattern.
Phosphorylation of Tyr 418 of Src was inhibited after knocking down p62/IMP2. Activated
proto-oncogene tyrosine kinase Src can enhance the cap-dependent translation, and thus elevate
the expression of β-catenin accumulation and its transcriptional activity. Tyr 418 and Tyr 529 are
two major phosphorylation sites on Src, Tyr 418 can be auto-phosphorylated, and then displaced
from binding pockets to allow substrate access. On the contrary, phosphorylated Tyr 529 can let
the tyrosine group interact with SH2 domain and inactive Src [121]. In addition, the reduced ser
21 on GSK3α also downregulated Wnt signaling. We did not observe the phosphorylation
change on β-catenin, which may explain why the downregulation of β-catenin is less in
p62/IMP2 knockdown cells of HepG2 cells than SNU449 cells (Fig. 24).
Wnt5a can induce CaMKII to weaken the protein stability of a co-repressor of Notch
signaling and the silencing mediator of retinoic acid and thyroid hormone receptor (SMRT).
Phosphorylated Tyr 287 of CaMKII (Tyr 286 in the α isoform) plays an important role in it:
increase more than 1000-fold binding affinity between CaM and CaMKII; preventing
auto-inhibition when CaM dissociates from CaMKII due to [Ca2+] i decrease [122]. Moreover,
CaMKII can phosphorylate Ser 537 of PLCβ3 and thus enhance its basal activity [123]. Our
phosphoproteome analysis data supported that loss of p62/IMP2 augments the Wnt5-mediated
non-canonical Wnt signaling, thereby explaining why colony formation ability is improved in
SNU449 IMP2 knockdown cells. Our results showed that p62/IMP2 regulates the
Wnt/beta-catenin pathway through multiple pathways: regulation of mRNA expression, affecting
multiple upstream and downstream genes and changes of phosphorylation levels.
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In the differential gene expression analysis, we found that 900 genes were regulated by the
change of expression; in addition, their encoded proteins were mainly distributed in the cell
membrane and cytoplasm, rather than in the nucleus. Another study showed that 3 percent of the
HEK293 cell transcriptome will be expressed in IMP1 messenger ribonucleoprotein (mRNP)
particles, which implies that there may be over 1000 targets of IMP1 [124]. Given that IMP
family members share a highly conserved structure with 60%-80% identity amino acid sequences
[125], there may be many unknown IMP2 targets in these differentially expressed genes, which
can help regulate complex pathways, their phosphorylation and improve the migration ability of
cancer cells.
In summary, our study revealed that p62/IMP2 is overexpressed in human HCC tissues and
cancer cell lines, thereby augmenting cell migration ability through activation of the canonical
Wnt signaling pathway. In SNU449 p62/IMP2 knockdown cells, colony formation ability was
promoted by noncanonical Wnt pathway. Our differential expression analysis indicates that
abnormally high expression of p62/IMP2 in HCC may regulate cells through a variety of
pathways, resulting in more malignant HCC phenotypes.
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7.2 Future directions
7.2.1 To explore novel mRNA targets of p62/IMP2 and evaluate their value as early
diagnosis biomarkers
Recently, more and more novel targets of IMPs have been identified. Due to the highly
conserved structure and similar function of IMPs, p62/IMP2 may have a plenty of unknown
binding targets. To identify novel targets of p62/IMP2, RNA immunoprecipitation will be used
firstly to isolate the mRNA that bind with p62/IMP2 in cytoplasm. We will collect cell lysates
from p62/IMP2-positive cells and use the p62/IMP2 antibody to precipitate the entire complex of
p62/IMP2-target from cell lysates. The target mRNA is finally isolated and separated by a
solution for reverse transcription using a RIP-Assay kit. Subsequently, we plan to use RNA
sequencing and qPCR to analyze the isolated RNA and obtain the list of p62/IMP2 targets. After
that, we will design a mini-array including p62/IMP2 and its potential targets as well as other
characterized TAAs to further enhance the autoantibody detection efficiency in the diagnosis of
HCC. ELISA will be used to examine the autoantibodies expression level. The data will be
presented as means ± standard deviation (SD). Unpaired two-tailed t test was used to compare
different groups.

Receiver operating characteristic (ROC) analysis was performed to evaluate

the diagnostic value for each TAA, which leading to calculate the area under the curve (AUC).
We expect to identify some novel TAAs and enhance the early diagnosis accuracy through our
future directions.
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7.2.2 To determine the role of p62/IMP in HCC by in vivo study
In this project, our data from in vitro studies demonstrated that p62/IMP2 can promote cell
migration ability in HCC via activation of Wnt/ β-catenin signaling pathway. To verify our
results, the HCC cell variants will be injected into the subcutaneous tissue. Thereafter, the body
weight and tumor size of the mice will be recorded daily. After 3-4 weeks, the mice will be
dissected, while the primary tumor and metastatic tumor will be taken out for analysis. The
metastatic sites of primary liver cancer are mainly concentrated in the lungs and bones, so we
will focus on their metastatic tumors for collecting statistical data. We will also analyze the
molecular biology differences between metastatic tumors and primary tumors.

77

References
1. World

Cancer

Report

2014.

World

Health

Organization.

2014.

pp. Chapter

5.6. ISBN 9283204298.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics,
2012. CA Cancer J Clin. 2015;65(2):87-108
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J
Clin. 2005;55:74–108.
4. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology,
and carcinogenesis. J Carcinog. 2017;16:1.
5. Choo SP, Tan WL, Goh BK, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in
Eastern versus Western populations. Cancer. 2016; 122 (22): 3430–3446.
6. American Cancer Society. Cancer Facts &Figures 2017. Atlanta: American Cancer Society;
2017.
7. Forner A, Llovet JM, Bruix. Hepatocellular carcinoma. The Lancet. 2012; 379 (9822): 1245–
1255
8. Liu, J. & Fan, D. Hepatitis B in China. Lancet. 2007; 369, 1582–1583 (2007).
9. Alter MJ. Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology.
2007; 13 (17): 2436–41.
10. Heidelbaugh JJ.; Bruderly M. "Cirrhosis and chronic liver failure: part I. Diagnosis and
evaluation". American Family Physician. 2006; 74 (5): 756–762.
11. Omer RE, Kuijsten A, Kadaru AMY, et al. Population-attributable risk of dietary aflatoxins
and hepatitis B virus infection with respect to hepatocellular carcinoma. Nutr Cancer.
2004;48(1):15-21.
12. Kew MC.

Hepatic Iron Overload and Hepatocellular

2014;3(1):31-40.

78

Carcinoma. Liver Cancer.

13. White DL, Kanwal F, El-Serag HB. Non-Alcoholic Fatty Liver Disease and Hepatocellular
Cancer: A Systematic Review. Clinical gastroenterology and hepatology : the official clinical
practice journal of the American Gastroenterological Association. 2012;10(12):1342-1359.
14. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular
carcinoma:

A

systematic

review

of

epidemiologic

evidence. Clin

Gastroenterol

Hepatol. 2006;4:369–380.
15. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated
analysis of somatic mutations and focal copy-number changes identifies key genes and
pathways in hepatocellular carcinoma. Nat Genet. 2012;44(6):694-8.
16. Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas
identifies new mutational signatures and potential therapeutic targets. Nat Genet.
2015;47(5):505-511.
17. Coste A de L, Romagnolo B, Billuart P, et al. Somatic mutations of the β-catenin gene are
frequent in mouse and human hepatocellular carcinomas. Proceedings of the National
Academy of Sciences of the United States of America. 1998;95(15):8847-8851.
18. Audard V, Grimber G, Elie C, Radenen B, Audebourg A, Letourneur F, et al. Cholestasis is a
marker

for

hepatocellular

carcinomas

displaying

beta-catenin

mutations. J

Pathol 2007;212:345-52.
19. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53
gene in human hepatocellular carcinomas. Nature. 1991;350(6317):427-8.
20. Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase
promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nature
Communications. 2013;4:2218.
21. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular
carcinoma. Gastroenterology. 2008;134(6):1752-63.

79

22. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic
resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review.
Am J Gastroenterol. 2006;101(3):513-523.
23. An C, Rakhmonova G, Choi JY, Kim MJ. Liver imaging reporting and data system
(LI-RADS) version 2014: understanding and application of the diagnostic algorithm. Clin
Mol Hepatol. 2016;22(2):296-307.
24. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of
Liver Diseases Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.
25. Tan, E. M. and J. Zhang. Autoantibodies to tumor-associated antigens: reporters from the
immune system. Immunol Rev 2008; 222: 328-340.
26. Old, L. J. and Y. T. Chen. New paths in human cancer serology. J Exp Med 1998;187(8):
1163-1167.
27. Desmetz C, Maudelonde T, Mange A, Solassol J. Identifying autoantibody signatures in
cancer: a promising challenge. Expert Rev Proteomic. 2009;6(4):377-386.
28. Imai H, Chan EK, Kiyosawa K, Fu XD, Tan EM. Novel nuclear autoantigen with splicing
factor motifs identified with antibody from hepatocellular carcinoma. Journal of Clinical
Investigation. 1993;92(5):2419-2426.
29. Zhang JY, Chan EKL, Peng XX, Tan EM. A novel cytoplasmic protein with RNA-binding
motifs

is

an

autoantigen

in

human

hepatocellular

carcinoma.

J

Exp

Med.

1999;189(7):1101-1110.
30. Hoo LS, Zhang JY, Chan EKL. Cloning and characterization of a novel 90 kDa 'companion'
auto-antigen of p62 overexpressed in cancer. Oncogene. 2002;21(32):5006-5015.
31. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging
classification. Semin Liver Dis. 1999;19(3):329-338.
32. Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based
medicine. World Journal of Gastroenterology : WJG. 2014;20(15):4115-4127.

80

33. Forner A, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: is there proof of
survival benefit? J Hepatol. 2012;56:984–986.
34. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A,
Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 2008;359:378–390.
35. Jiang XJ, Wang J, Deng XY, et al. Role of the tumor microenvironment in
PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18.
36. Li G, Cai G, Li D, Yin W. MicroRNAs and liver disease: viral hepatitis, liver fibrosis and
hepatocellular carcinoma. Postgrad Med J. 2014;90(1060):106-112.
37. Long L, Zhang X, Chen F, et al. The promising immune checkpoint LAG-3: from tumor
microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5-6):176–189.
38. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and
Implications of Their Inhibition. Am J Clin Oncol. 2016;39(1):98–106.
39. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by
a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med.
2000;192(7):1027-1034.
40. Latchman Y, Wood C, Chemova T, et al. PD-L2, a novel B7 homologue, is a second ligand
for PD-1 and inhibits T cell activation. Faseb J. 2001;15(4):A345-A345.
41. Cemerski S, Das J, Giurisato E, Markiewicz MA, et al. The balance between T cell receptor
signaling and degradation at the center of the immunological synapse is determined by
antigen quality. Immunity. 2008;29(3):414-22.
42. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in Regulating T-Cell Immunity. Curr Top
Microbiol. 2011;350:17-37.
43. Barber DL, Wherry EJ, Masopust D, Zhu BG, et al. Restoring function in exhausted CD8 T
cells during chronic viral infection. Nature. 2006;439(7077):682-7.
44. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed Death Ligand 2
in Cancer-Induced Immune Suppression. Clin Dev Immunol. 2012.

81

45. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy.

Nature

Reviews Cancer 2012, 12(4):252-264.
46. von Boehmer H: Mechanisms of suppression by suppressor T cells. Nature immunology
2005, 6(4):338-344.
47. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev
Cancer 2005;5:591-602.
48. Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nature Reviews Cancer.
2018;18(2):128-134.
49. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in
development and disease. Cell. 2009;139(5):871-890.
50. Yang J, Weinberg RA. Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 2008;14(6):818-29.
51. Zhai

B, Yan

HX, Liu

E-cadherin/catenin

SQ, Chen

complex

L, Wu
in

MC, Wang
hepatocellular

HY. Reduced

expression

carcinomas. World

of
J

Gastroenterol. 2008;14:5665-5673.
52. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an
alliance against the epithelial phenotype? Nature Reviews Cancer. 2007;7(6):415-428.
53. Yang MH, Chen CL, Chau GY, et al. Comprehensive Analysis of the Independent Effect of
Twist and Snail in Promoting Metastasis of Hepatocellular Carcinoma. Hepatology.
2009;50(5):1464-1474.
54. del Castillo G, Murillo MM, Alvarez-Barrientos A, et al. Autocrine production of TGF-beta
confers resistance to apoptosis after an epithelial-mesenchymal transition process in
hepatocytes: Role of EGF receptor ligands. Exp Cell Res. 2006;312(15):2860-2871.
55. Syed V. TGF-beta Signaling in Cancer. J Cell Biochem. 2016;117(6):1279-1287.
56. Hoot KE, Lighthall J, Han G, et al. Keratinocyte-specific Smad2 ablation results in increased
epithelial-mesenchymal transition during skin cancer formation and progression. Journal of
Clinical Investigation. 2008;118(8):2722-2732.
82

57. Shirakihara T, Saitoh M, Miyazono K. Differential regulation of epithelial and mesenchymal
markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta.
Mol Biol Cell. 2007;18(9):3533-3544.
58. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A. Transforming
growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol.
2006;174(2):175-183.
59. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the
polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science.
2005;307(5715):1603-1609.
60. Lamouille S, Connolly E, Smyth JW, Akhurst RJ, Derynck R. TGF-beta-induced activation
of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci.
2012;125(5):1259-1273.
61. Marchetti A, Colletti M, Cozzolino AM, et al. ERK5/MAPK is activated by TGF beta in
hepatocytes and required for the GSK-3 beta-mediated Snail protein stabilization. Cell Signal.
2008;20(11):2113-2118.
62. Yamashita M, Fatyol K, Jin CY, Wang XC, Liu ZG, Zhang YE. TRAF6 mediates
Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell. 2008;31(6):918-924.
63. Santibanez

JF.

JNK

mediates

TGF-beta

1-induced

epithelial

mesenchymal

transdifferentiation of mouse transformed keratinocytes. Febs Lett. 2006;580(22):5385-5391.
64. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Bio.
2012;13(12):767-779.
65. Stamos JL, Weis WI. The β-Catenin Destruction Complex. Cold Spring Harbor Perspectives
in Biology. 2013;5(1):a007898.
66. Wehrli M, Dougan ST, Caldwell K, et al. arrow encodes an LDL-receptor-related protein
essential for Wingless signalling. Nature. 2000;407(6803):527-30.
67. Mao JH, Wang JY, Liu B, et al. Low-density lipoprotein receptor-related protein-5 binds to
Axin and regulates the canonical Wnt signaling pathway. Mol Cell. 2001;7(4):801-9.

83

68. Staal FJ, Meeldijk J, Moerer P, et al. Wnt signaling is required for thymocyte development
and activates Tcf-1 mediated transcription. Eur J Immunol. 2001;31(1):285-93.
69. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma
cells. Nature. 1999;398(6726):422-6.
70. Hori K, Sen A, Artavanis-Tsakonas S. Notch signaling at a glance. J Cell Sci.
2013;126(10):2135-2140.
71. Bell JL, Wachter K, Muhleck B, et al. Insulin-like growth factor 2 mRNA-binding proteins
(IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci.
2013;70(15):2657-75.
72. Nielsen J, Nielsen FC, et al. A family of insulin-like growth factor II mRNA-binding proteins
represses translation in late development. Mol Cell Biol. 1999;19(2):1262-70
73. Christiansen J, Kolte AM, Hansen Tv, Nielsen FC. IGF2 mRNA-binding protein 2: biological
function and putative role in type 2 diabetes. J Mol Endocrinol. 2009;43(5):187-95.
74. Griffin D, Penberthy WT, Lum H, Stein RW, Taylor WL. Isolation of the B3 transcription
factor of the Xenopus TFIIIA gene. Gene. 2003;313:179-188.
75. Farina KL, Huttelmaier S, Musunuru K, Darnell R, Singer RH.

Two ZBP1 KH domains

facilitate beta-actin mRNA localization, granule formation, and cytoskeletal attachment. J
Cell Biol. 2003; 160(1):77–87
76. Maris C, Dominguez C, Allain FH. The RNA recognition motif, a plastic RNA-binding
platform to regulate post-transcriptional gene expression. FEBS J. 2005;272(9):2118-31.
77. Chao JA, Patskovsky Y, Patel V, Levy M, Almo SC, Singer RH. ZBP1 recognition of β-actin
zipcode induces RNA looping. Genes & Development. 2010;24(2):148-158.
78. Mori H, Sakakibara S, Imai T, Nakamura Y, Iijima T, Suzuki A, Yuasa Y, Takeda M, Okano
H. Expression of mouse igf2 mRNA-binding protein 3 and its implications for the developing
central nervous system. J Neurosci Res 2001; 64: 132–143.

84

79. Hansen TVO, Hammer NA, Nielsen J, et al. Dwarfism and Impaired Gut Development in
Insulin-Like Growth Factor II mRNA-Binding Protein 1-Deficient Mice. Molecular and
Cellular Biology. 2004;24(10):4448-4464. doi:10.1128/MCB.24.10.4448-4464.2004.
80. Nishino J, Kim I, Chada K, Morrison SJ. Hmga2 promotes neural stem cell self-renewal in
young,

but

not

old,

mice

by

reducing

p16Ink4a and

p19Arfexpression. Cell.

2008;135(2):227-239.
81. Fujii Y, Kishi Y, Gotoh Y. 2013. IMP2 regulates differentiation potentials of mouse
neocortical neural precursor cells. Genes Cells 18: 79–89.
82. Doyle GA, Betz NA, Ross J, et al. The c-myc coding region determinant-binding protein: a
member of a family of KH domain RNA-binding proteins. Nucleic Acids Res. 1998 Nov
15;26(22):5036-44.
83. Li Z, Gilbert JA, Zhang Y, et al. An HMGA2-IGF2BP2 Axis Regulates Myoblast
Proliferation and Myogenesis. Developmental cell. 2012;23(6):1176-1188.
84. Jonson L, Vikesaa J, Krogh A, Nielsen LK, Hansen T, Borup R, Johnsen AH, Christiansen J,
Nielsen FC Molecular composition of IMP1 ribonucleoprotein granules. Mol Cell
Proteomics. 2007; 6(5):798–811
85. Ross AF, Oleynikov Y, Singer RH, et al. Characterization of a beta-actin mRNA
zipcode-binding protein. Mol Cell Biol. 1997;17(4):2158-65.
86. Hüttelmaier S, Zenklusen D, Singer RH, et al. Spatial regulation of beta-actin translation by
Src-dependent phosphorylation of ZBP1. Nature. 2005;438(7067):512-5.
87. Doyle GA, Bourdeau-Heller JM, Ross J, et al. Amplification in human breast cancer of a
gene encoding a c-myc mRNA-binding protein. Cancer Res. 2000;60(11):2756-9.
88. Boyerinas B, Park SM, Shomron N, et al. Identification of let-7-regulated oncofetal genes.
Cancer Res. 2008;68(8):2587-2591.
89. Shenoy A, Danial M, Blelloch RH. Let-7 and miR-125 cooperate to prime progenitors for
astrogliogenesis. The EMBO Journal. 2015;34(9):1180-1194.

85

90. Boyerinas B, Park S-M, Murmann AE, et al. Let-7 modulates acquired resistance of ovarian
cancer to Taxanes via IMP-1-mediated stabilization of MDR1. International Journal of
Cancer Journal International du Cancer. 2012;130(8):1787-1797.
91. Vikesaa J, Hansen TVO, Jønson L, et al. RNA-binding IMPs promote cell adhesion and
invadopodia formation. The EMBO Journal. 2006;25(7):1456-1468.
92. Runge S, Nielsen FC, Nielsen J, Lykke-Andersen J, Wewer UM, Christiansen J (2000) H19
RNA binds four molecules of insulinlike growth factor II mRNA-binding protein. J Biol
Chem 275(38):29562–29569
93. Jonson L, Christiansen J, Hansen TVO, Vikesa J, Yamamoto Y, Nielsen FC. IMP3 RNP Safe
Houses Prevent miRNA-Directed HMGA2 mRNA Decay in Cancer and Development. Cell
Rep. 2014;7(2):539-551.
94. Cleynen I, Brants JR, Petit MM, et al. HMGA2 regulates transcription of the Imp2 gene via
an intronic regulatory element in cooperation with nuclear factor-kappaB. Mol Cancer Res.
2007;5(4):363-72.
95. Morishita A, Zaidi MR, Chada K, et al. HMGA2 is a driver of tumor metastasis. Cancer Res.
2013;73(14):4289-99.
96. Li Y, Francia G, Zhang J-Y. p62/IMP2 stimulates cell migration and reduces cell adhesion in
breast cancer. Oncotarget. 2015;6(32):32656-32668.
97. Hosen MR, Militello G, Weirick TM, Ponomareva Y, Dassanayaka S, Moore JB, et al. Airn
Regulates Igf2bp2 Translation in Cardiomyocytes. Circ Res. 2018.
98. Mu Q, Wang L, Yu F, et al. Imp2 regulates GBM progression by activating IGF2/PI3K/Akt
pathway. Cancer Biology & Therapy. 2015;16(4):623-633.
99. Er L-M, Li Y, Wu M-L, et al. Expression of IMP3 as a marker for predicting poor outcome
in

gastroenteropancreatic

neuroendocrine

2017;13(4):2391-2396.

86

neoplasms. Oncology

Letters.

100. Barghash A, Golob-Schwarzl N, Helms V, Haybaeck J, Kessler SM. Elevated expression of
the IGF2 mRNA binding protein 2 (IGF2BP2/IMP2) is linked to short survival and
metastasis in esophageal adenocarcinoma. Oncotarget. 2016;7(31):49743-49750.
101. Dai N, Ji F, Wright J, Minichiello L, Sadreyev R, Avruch J. IGF2 mRNA binding protein-2
is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and
HMGA1. Elife. 2017;6.
102. Boudoukha S, Cuvellier S, Polesskaya A. Role of the RNA-binding protein IMP-2 in muscle
cell motility. Mol Cell Biol. 2010; 30(24):5710-25.
103. Kim HY, Ha Thi HT, Hong S. IMP2 and IMP3 cooperate to promote the metastasis of
triple-negative breast cancer through destabilization of progesterone receptor. Cancer Lett.
2018;415:30-9.
104. Kessler SM, Laggai S, Barghash A, et al. IMP2/p62 induces genomic instability and an
aggressive hepatocellular carcinoma phenotype. Cell Death & Disease. 2015;6(10):e1894-.
105. Suzuki T, Yano H, Nakashima Y, Nakashima O, Kojiro M. beta-Catenin expression in
hepatocellular carcinoma: A possible participation of beta-catenin in the dedifferentiation
process. J Gastroen Hepatol. 2002;17(9):994-1000.
106. Janiszewska M, Suva ML, Riggi N, et al. Imp2 controls oxidative phosphorylation and is
crucial for preserving glioblastoma cancer stem cells. Gene Dev. 2012;26(17):1926-1944.
107. Dai LP, Ren PF, Liu M, Imai H, Tan EM, Zhang JY. Using immunomic approach to enhance
tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma. Clin
Immunol. 2014;152(1-2):127-139.
108. Zaenker P, Gray ES, Ziman MR. Autoantibody Production in Cancer-The Humoral Immune
Response

toward

Autologous

Antigens

2016;15(5):477-483.
87

in

Cancer

Patients.

Autoimmun

Rev.

109. Koziol JA, Imai H, Dai LP, Zhang JY, Tan EM. Early detection of hepatocellular carcinoma
using autoantibody profiles from a panel of tumor-associated antigens. Cancer Immunol
Immun. 2018;67(5):835-841.
110. Nelson WJ. Regulation of cell-cell adhesion by the cadherin-catenin complex. Biochem Soc
Trans 2008;36:149-155.
111. Zucchini-Pascal N, Peyre L, Rahmani R. Crosstalk between Beta-Catenin and Snail in the
Induction of Epithelial to Mesenchymal Transition in Hepatocarcinoma: Role of the ERK1/2
Pathway. Int J Mol Sci. 2013;14(10):20768-20792.
112. Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW, MacBeath G. A Noncanonical
Frizzled2 Pathway Regulates Epithelial-Mesenchymal Transition and Metastasis. Cell.
2014;159(4):844-856.
113. Yuzugullu H, Benhaj K, Ozturk N, et al. Canonical Wnt signaling is antagonized by
noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer. 2009;8.
114. Verheyen EM, Gottardi CJ. Regulation of Wnt/beta-catenin signaling by protein kinases. Dev
Dyn. 2010;239(1):34-44.
115. Stamos JL, Weis WI. The beta-catenin destruction complex. Cold Spring Harb Perspect Biol.
2013;5(1):a007898.
116. Amit S, Hatzubai A, Birman Y, et al. Axin-mediated CKI phosphorylation of beta-catenin at
Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 2002;16(9):1066-1076.
117. Wu G, Huang H, Garcia Abreu J, He X. Inhibition of GSK3 phosphorylation of beta-catenin
via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6. PLoS One. 2009;4(3):e4926.
88

118. van Veelen W, Le NH, Helvensteijn W, et al. beta-catenin tyrosine 654 phosphorylation
increases Wnt signalling and intestinal tumorigenesis. Gut. 2011;60(9):1204-1212.
119. Neufeld KL, Zhang F, Cullen BR, White RL. APC-mediated downregulation of beta-catenin
activity involves nuclear sequestration and nuclear export. EMBO Rep. 2000;1(6):519-523.
120. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen
synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378(6559):785-789.
121. Roskoski R, Jr. Src kinase regulation by phosphorylation and dephosphorylation. Biochem
Biophys Res Commun. 2005;331(1):1-14.
122. Ann EJ, Kim HY, Seo MS, et al. Wnt5a controls Notch1 signaling through
CaMKII-mediated degradation of the SMRT corepressor protein. J Biol Chem.
2012;287(44):36814-36829.
123. Hatziapostolou M, Koukos G, Polytarchou C, et al. Tumor progression locus 2 mediates
signal-induced increases in cytoplasmic calcium and cell migration. Sci Signal.
2011;4(187):ra55.
124. Ross AF, Oleynikov Y, Kislauskis EH, Taneja KL, Singer RH. Characterization of a
beta-actin mRNA zipcode-binding protein. Mol Cell Biol. 1997;17(4):2158-2165.
125. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family
of insulin-like growth factor II mRNA-binding proteins represses translation in late
development. Mol Cell Biol. 1999;19(2):1262-1270.

89

Appendix I
List of abbreviations
APC - Adenomatous polyposis coli
BCLC – Barcelona clinic liver cancer
CDKN2A - Cyclin dependent kinase inhibitor 2A
CIP2A - Cancerous inhibitor of protein phosphatase 2A
DAPI - 4’,6’-diamidino-2-phenylindole
DEG - Differential expression gene
ECL- Enhanced chemiluminescence
ELISA - Enzyme linked immunosorbent assay
EMT - Epithelial mesenchymal transition
ERK - Extracellular signal-regulated kinases
EGFR - Epidermal growth factor receptor
FGF - Fibroblast growth factor
GEO - Gene omnibus
HCC - Hepatocellular carcinoma
HRP - Horseradish peroxidase
IHC- Immunohistochemistry
IMP - Insulin-like growth factor 2 mRNA binding protein
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LEF - Lymphoid enhancer binding factor
MAPK - mitogen-activated protein kinase
mTOR - Mammalian target of rapamycin
NHS - Normal human sera
OD - Optical density
PBS - Phosphate-buffered saline
PI3K - Phosphoinositide 3-kinases
PKB - Protein kinase B
TBS – Tris base saline
TCF - Transcription Factor
TERT – Telomerase reverse transcriptase
TSC - Tuberous sclerosis 1
ZEB - Zinc finger E-Box binding homeobox
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